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ABSTRACT 
 
The efficacy of information transfer at synaptic contacts between excitatory 
central neurons undergoes continual modification in response to neuronal activity and 
physiological state. This plasticity in synaptic transmission may involve changes in 
presynaptic release probability, postsynaptic receptor number and sensitivity, and/or 
synaptic morphology. The molecular mechanisms influencing these distinctive targets 
are an investigative focus given their importance in learning, memory, and cognitive 
function. Much attention has focused on transcriptional and translational regulation of 
the synapse, but post-translational modification and directed turnover of specific protein 
components is also recognized as critical. Central to targeted protein degradation is the 
ubiquitin-proteasome system (UPS). While an increasing number of synaptic proteins 
are known to be susceptible to activity-dependent regulation by the UPS, relatively little 
has focused on the action of the UPS on known negative regulators of synaptic function. 
The SNARE protein Tomosyn-1 (Tomo-1) directly inhibits evoked release at central 
synapses, but it is also present post-synaptically, where no known function has been 
identified. It was recently discovered that the related Tomosyn-2 protein is subject to 
ubiquitination and degradation in neuroendocrine pancreatic beta cells, suggesting their 
secretory activity may be under control of the UPS. The general hypothesis of this 
	 ix	
dissertation is that a central mechanism underlying modulation of the synapse is the 
targeted degradation of Tomo-1. 
 This dissertation made use of a series of complementary biochemical, molecular, 
and imaging technologies in hippocampal neuronal culture. We demonstrate that Tomo-
1 protein level, independently of its SNARE domain, positively correlates with 
postsynaptic dendritic spine density in vivo. The data also indicate that the UPS 
regulates steady-state Tomo-1 level and function. Immunoprecipitated Tomo-1 was 
ubiquitinated and co-precipitated the E3 ligase HRD1, and both effects dramatically 
increased upon proteasome inhibition. The interaction was also found in situ, via fixed-
cell proximity ligation assay. In vitro reactions indicated direct, HRD1 concentration-
dependent Tomo-1 ubiquitination. Furthermore, we demonstrated that neuronal HRD1 
knockdown increased Tomo-1 level, and consequently, dendritic spine density. This 
effect was abrogated by concurrent knockdown of Tomo-1, strongly suggesting a direct 
HRD1/Tomo-1 effector relationship. We confirmed Tomo-1 is a UPS substrate by 
identifying 12 lysine residues which are ubiquitinated by HRD1 and generated a non-
ubiquitinateable Tomo-1 mutant. Finally, we performed Tomo-1 isoform and homologue 
comparisons, protein structure modeling, and antibody-based domain targeting of 
Tomo-1 in neuronal lysates to identify four lysine residues which are highly likely to be 
ubiquitinated in vivo. In summary, the results of this dissertation indicate that the UPS 
participates in tuning synaptic efficacy via the precise regulation of neuronal Tomo-1 
and spine density. These findings implicate Tomo-1 as a prime target of UPS mediated 
degradation in the implementation of morphological plasticity in central neurons. 
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CHAPTER I 
Introduction: The proteostasis of synaptic proteins modulates neurotransmission 
 
1.1 Fundamental units: The physiology of synapses 
Chemical neurotransmission, namely neurotransmitter release and reception at 
the synapse, serves an integral function in the efficient transfer of information within the 
brain. Consequently, the synapse can be viewed as a foundational unit for information 
encoding in central and peripheral nervous systems. The cellular and molecular 
mechanisms which underlie synaptic physiology, including both the fusion of 
neurotransmitter-containing presynaptic vesicles and the resultant activation of 
postsynaptic neurotransmitter receptors, coalesce to govern interneuronal signaling. 
Neuronal communication among networks is at least in part responsible for sensory 
perception, motor function, organismal homeostasis, memory formation and stability, 
and cognition. Therefore, examination of the diverse regulatory mechanisms which 
dictate the availability and activity of synaptic proteins is crucial to understanding 
neuronal biology in health and disease, notably including Alzheimer’s and Parkinson’s 
Diseases and Autism Spectrum Disorder. 
 
Calcium-synchronized evoked release 
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Neurons are highly specialized cells which communicate with exceptional spatial 
and temporal fidelity to meet a wide range of physiological demands. Upon action 
potential (AP) initiation at the axon initial segment and orthodromic propagation down 
the axon, a complex system of biochemical interactions is employed in a step-wise, but 
extremely rapid fashion at presynaptic terminals (1). This process ultimately results in 
the fusion of neurotransmitter (NT)-containing synaptic vesicles (SVs) at the active zone 
(AZ) of the presynaptic membrane, which is directly apposed to the NT receptor-rich 
postsynaptic density across the synaptic cleft. Amazingly, the extensive biophysical 
conformational changes and protein interactions required for SV fusion all occur within 
the timescale of a millisecond (2). The SV fusion process is primarily mediated by 
cycling interactions of soluble NSF (N-ethylmaleimide-sensitive fusion protein) 
attachment protein receptor (SNARE) and Sec1/Munc18-like (SM) and Munc13 family 
proteins (3). These proteins function as biomolecular nanomachines and are driven by 
AP-mediated presynaptic calcium influx through voltage-gated Ca2+-channels (4). The 
channels are tethered in close proximity to vesicle release sites by Rab3-interacting 
molecule (RIM), considered to be a central organizer of the AZ, the small GTPase 
Rab3, and the exocytosis-essential Munc13 in addition to RIM-binding proteins (5). 
Rab3 is a member of a large superfamily of GTPase proteins that regulate intracellular 
membrane trafficking, including of SVs, via membrane associations dependent upon 
GDP/GTP-cycling (6). This multi-protein module of RIM, Rab3, and Munc13 is reported 
to facilitate the voltage-gated Ca2+-channels to rapidly conduct calcium ions directly into 
the presynaptic terminal within hundreds of microseconds (7). Pore opening drastically 
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increases the calcium concentration within the first ≈ 50 nanometers of the channel, 
facilitating synchronous neurotransmitter release, which then rapidly drops within the 
first few hundred nanometers and may contribute to asynchronous release (8). 
Increased [Ca2+] activates regulatory proteins including the complexins, which act as 
clamps on release by binding the SNARE core complex, and the calcium sensor family 
of proteins termed the synaptotagmins, which physically bind calcium via their C2 
domains to regulate fusion of the SV with the presynaptic plasma membrane (PM) at 
the AZ (9). It is to these release sites that the SVs have been recruited or locally 
recycled. Indeed many are anchored or “docked” in close proximity to the PM via the 
SM Munc18 (10), which like Munc13, is absolutely essential for neuronal exocytosis. 
Only a small number of docked SVs are completely fusion-competent or 
morphologically “primed” (11), awaiting presynaptic terminal depolarization-induced 
calcium influx. This coupling affords the cell minimal delay in translating an AP to 
vesicle fusion, ultimately presenting the synaptic cleft with their NT content. 
 
SNARE-mediated vesicle fusion at the active zone 
The detailed molecular mechanisms underlying SV fusion with the PM have been 
extensively investigated over the past three decades, a process in which SNARE-family 
proteins are essential. SNAREs execute many functions within eukaryotic cells, but are 
primarily responsible for mediating membrane fusion with target organelles and are 
most well-studied in neurons in the context of SV targeting and fusion with the 
presynaptic plasma membrane. There are now upwards of 35 identified SNARE 
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proteins in humans, which share an evolutionarily conserved motif of 60-70 amino 
acids, termed the SNARE domain (12). The most well-characterized SNARE proteins in 
the context of vesicle fusion are the VAMPs (vesicle-associated membrane proteins, 
also known as synaptobrevins), which span the membranes enclosing synaptic vesicles 
(so-called v-SNAREs for vesicular, or R-SNAREs for an arginine at the 0 core of the 
SNARE motif), and the syntaxins and SNAP25, which are also membrane delimited, but 
are integrated into the PM (t-SNAREs for target, or Q-SNAREs for a glutamine at the 0 
core of the SNARE motif) rather than that of the SV (13). VAMP and Syntaxin proteins 
contain a C-terminal membrane anchor, while SNAP25 contains a cysteine-rich 
palmitoylated domain between its two SNARE domains which act as pivot points during 
SV priming, allowing a heterotrimeric trans-SNARE complex comprising four SNARE 
domains to form between the three proteins – termed the SNARE core complex. The 
AAA+-ATPase known as NSF is required to disassemble SNARE complexes post-
fusion, thereby exerting a functional role in energizing the formation of core complexes. 
Trans-SNARE core complexes physically link the SV to the PM and ultimately act as 
engines to drive fusion. SNARE core complexes are highly stable and comprise the 
release apparatus alongside other membrane-bound and associated soluble/cytosolic 
proteins such as Munc18, RIM, and RIM-binding proteins in addition to signaling lipids 
(14). The SNARE proteins then “zipper” from the N-terminal regions of the core 
complex’s coiled 4-helix bundle toward their C-terminal membrane anchors, which 
brings the vesicle in direct apposition to the PM and catalyzes trans-fusion of the lipid 
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bilayers. This lipid fusion is then immediately followed by formation of a fusion pore and 
consequential initiation of NT release directly into the synaptic cleft (15). 
Following full collapse of the vesicle, the membranes of the SV and PM are 
contiguous, and the now cis-SNARE complex is recycled by NSF and its adaptor α-
SNAP via ATP-hydrolysis-dependent mechanisms. In contrast to full fusion, “kiss-and-
run” fusion has been recognized, particularly in large dense core vesicles, as a more 
transient fusion pore opening event, whereby the vesicle only briefly fuses with the PM 
and then reseals, allowing it to forgo the more time- and energy-intensive vesicle 
recycling pathway prior to SV refilling (16). For example, in the event of full fusion, the 
SV membrane is extracted from the PM via a physical process termed endocytosis, 
which is primarily dependent upon clathrin and dynamin for invagination and fission (17, 
18). These newly re-formed vesicles are then sorted through an endosomal recycling 
pathway, or in some cases faster reuse is facilitated by local recycling and refilling with 
NT. The latter of these routes also bypasses some of the extensive cell biological 
mechanisms which are implemented during vesicle maturation, targeting, and sorting 
amongst functionally distinct pools. 
 
Synaptic vesicles and their functional pools 
Synaptic vesicles are 35-40nm in diameter and are recognized to contain a 
dense and heterogeneous population of proteins. Notable among these are 
transmembrane proteins important for NT-loading (e.g. the vesicular glutamate 
transporters, or vGluTs, in glutamate-containing SVs) and membrane targeting and 
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trafficking (e.g. VAMP and synaptotagmin). Also present are various adaptor and other 
membrane-associated proteins such as the synapsins and Rab GTPases (19). 
Synapsin, an abundant phospho-protein, cycles on and off the SV membrane 
depending on its phosphorylation state. It is phosphorylated by Ca2+/calmodulin-
dependent protein kinase I (CaMKI) and protein kinase A (PKA), and is reported to 
contribute to the segregation of SVs into distinct presynaptic pools (20). This occurs 
primarily via synapsin binding with cytoskeletal actin and the vesicles themselves. 
Within central terminals SVs are functionally categorized into distinct pools based on 
their release probability following a single or series of action potentials, hypertonic 
osmotic challenge, or as morphologically determined based on their physical location. 
The readily-releasable pool (RRP) is the smallest (typically 5-10 vesicles at cortical and 
hippocampal synapses, or 0.1-2% of the total primed vesicle number (21)), and this pool 
is rapidly depleted upon high-frequency stimulation. Though in large dense-core 
vesicles of chromaffin cells of the adrenal medulla may not completely comprise the 
pool of docked vesicles, as judged by their location relative to the AZ, vesicles of the 
RRP are nonetheless considered primed given their rapid time constant of release upon 
stimulation (10-40µs at [20µM] Ca2+) (11). Therefore, not all RRP vesicles appear 
docked in all systems. A fraction of the RRP is sometimes also considered “pre-primed” 
or “rapidly releasing” due to their probability of release following basal physiological 
conditions (22). Next largest is the recycling pool (RP) at approximately 5-20% of the 
total, though this proportion varies between synapse types and experimental conditions 
such as temperature and cell preparation. These vesicles maintain release when 
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stimulated at moderate physiological frequencies and timescales. Finally, the largest 
pool (at approximately 80-95%) is known as the reserve or resting pool, which may act 
to increase or decrease the size of the RP and serves as an SV reservoir to refill the 
RRP during and following extended high-frequency stimulation or sustained 
depolarization. There is also what is considered an unprimed pool (UPP), which is 
comprised of vesicles that reside in the presynaptic terminal and near the AZ, yet are 
unable to undergo synchronized exocytosis upon calcium influx. Instead vesicles of the 
UPP are released asynchronously, more slowly and constantly on the timescale of 
several seconds (23). The summing of each pool’s properties gives rise to three kinetic 
modes of physiological SV exocytosis; a synchronous, a non-synchronous, and a 
spontaneous phase of release. It is important to note that each pool is dynamically 
tuned during and following activity via mechanisms that are not entirely understood. 
However, the local recycling of previously fused vesicles and the delivery and 
processing of nascent vesicles to the terminal are essential for SV pool maintenance 
and, consequently, efficient NT release. 
 
Postsynaptic signal reception 
The acute increase in neurotransmitter concentration present in the synaptic cleft 
following presynaptic SV exocytosis, most commonly glutamate in central excitatory 
synapses, acts directly on postsynaptic NT receptors. This process is more 
straightforward than vesicle fusion in the sense that activation of ionotropic 
transmembrane receptors, such as a class of glutamate receptors (GluRs), directly and 
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non-selectively conduct cations into the postsynaptic terminal. For example, glutamate-
sensitive AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor 
(AMPAR) permeability for sodium, potassium, and especially for calcium vary 
depending upon the channel’s subunit composition (24). Kainate (or kainic acid) 
receptors have similar conductances to AMPARs though they are typically slower and 
can have a lower conductance for Ca2+ in particular. Conversely, NMDA (N-methyl-D-
aspartate) receptors (NMDARs), which require glycine as a co-agonist and are blocked 
in the open state by Mg2+ at negatively polarized membrane potentials, have a high 
Ca2+ permeability (25). GluRs in most excitatory central neurons are responsible for 
postsynaptic current production, and with reversal potentials around 0mV, they 
depolarize the postsynaptic cell toward AP threshold. Their activation also causes 
postsynaptic intracellular signaling mechanisms which are involved in neuronal 
maintenance and homeostasis, protein translation, and plasticity induction. 
 
1.2 The adaptive brain: Hebbian and homeostatic plasticities in excitatory 
neurotransmission 
 An essential capacity of the brain is the establishment, maintenance, and 
reactivation/recall of use-dependent changes in neuronal morphology and activity – 
termed neuroplasticity. Plasticity is enacted on various scales, from individual 
subcellular compartments such as dendritic spines and/or presynaptic boutons, to 
networked ensembles of neurons, to whole brain regions and their interconnections. 
The most well-studied source of plasticity induction is activity-dependent, whereby a 
	 9	
stimulus modifies the activity of neurons and circuit formation and function, 
subsequently influencing memory, thought, emotion, and/or behavior. Indeed, 
converging theories on the physiological basis of memory describe its encoding as 
dependent upon the synchronized activity of specific spatio-temporal patterns of neural 
networks. Furthermore, the growing number of pathological cognition, motor function, 
learning, and memory issues apparent in various forms of neurological disorders and 
diseases are known to be associated with deficits in neuronal plasticity. For this reason, 
thorough examination and understanding of the mechanisms underlying plasticity are 
vital to the advancement of neuroscientific research and human health. 
 
Long-term facilitation and depression 
 Neuronal plasticity is one of the most extensively studied phenomena of the 
nervous system. It is categorized into short- and long-term, depending on its 
persistence (26). Short-term plasticity (STP) lasts milliseconds to minutes and is thought 
to heavily depend on the acute regulation of ion channel function through post-
translational modifications (PTMs) and the parameters of presynaptic Ca2+ entry and 
intracellular [Ca2+], with post-tetanic potentiation also relying in part on presynaptic 
intracellular [Na2+] (27). Long-term plasticity has been observed to last minutes to years, 
and is thought to rely on Ca2+ signaling, protein kinase activity, and mRNA synthesis 
and protein translation (25). Feedback-based alterations in the function of neurons are 
not specific to but are ubiquitously expressed in cortical and sub-cortical structures of 
vertebrates. These so-called Hebbian forms of plasticity, those which strengthen or 
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weaken in their efficiency depending on coincident pre- and post-synaptic activity, 
operate under a positive-feedback system. That is, networks subject to Hebbian 
plasticity are typically strengthened upon increased coincident activity and dampened 
following non-correlated. These robust alterations contribute to the reliable and efficient 
transfer of information while allowing for flexibility to an organism’s non-static 
environment. 
For example, long-term potentiation (LTP) is a form of synaptic strengthening 
originally identified following brief high-frequency stimulation of hippocampal afferents 
from neocortical areas (28), though it is now recognized to occur in potentially all 
regions of the brain and across a multitude of species (25). However, if occurring 
unchecked, LTP would be of no great consequence to the nervous system as a strictly 
feedforward loop. Not surprisingly, evolution has also afforded the ability for activity-
dependent and selective downregulation of the efficacy of neurotransmission. This 
counterpoint to LTP’s increase in presynaptic firing and postsynaptic response is known 
as long-term depression (LTD). LTD is most well-studied in the Schaffer-collateral 
synapses of the CA1 region of the hippocampus, where it is reliably induced upon 
extended low-frequency stimulation (0.5-3Hz) (29). Amazingly however, LTD was 
originally identified to occur in separate hippocampal inputs following the same stimulus 
that induced LTP in others (30). LTP and LTD can therefore be conceptualized as more 
a spectrum than discrete phenomena. Indeed, there are a multitude of sub-categories of 
LTP and LTD. Those which differ by induction site (i.e. pre- versus post-synaptic) may 
employ unique mechanisms in their implementation, yet produce the same outcome. 
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This further supports the hypothesis that an interplay between differential sites of 
induction is important, a notable example of such is spike-timing dependent plasticity 
(STDP). STDP results from the association between the timing of presynaptic activation 
versus that of the postsynaptic response (31). Importantly, STDP determines both the 
sign and the magnitude of LTP and LTD, potentiation occurring when presynaptic 
precede postsynaptic spikes and depression occurring when postsynaptic activity 
precedes presynaptic input. It is therefore concluded that LTP and LTD together, 
through local and global mechanisms within individual neurons and their networks, exert 
influence on higher order cognition, including memory. Furthermore, it may be a futile 
attempt to identify the mechanistic crux of memory induction - as there is likely no single 
point of master regulation. Instead, the brain implements an intricate balance of 
molecular biochemical, cell, and systems level phenomena, each subject to the 
mathematical principles of chaos and control theories, toward the establishment of 
complex and emergent physiological properties. Perhaps there are specific circuits or 
networks that must be specifically temporally or spatially activated to induce the 
formation, stabilization, or pruning of memories (i.e. those during sleep). Nonetheless, 
Hebbian forms of use-dependent, associative plasticity are considered to be the 
putative biological substrates of learning and memory. Relatedly, STP may be critical in 
affording the circuit temporary up- or down-regulation to drive the induction of LTP or 
LTD as an ultimate outcome of continuous and transient STP mechanisms. 
Consequently, examples of Hebbian plasticities, including LTP and LTD, are well-
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represented in the examination and evaluation of memory and experimental models 
thereof. 
 
Homeostatic synaptic plasticity 
Comparatively, homeostatic plasticity, the cell-intrinsic stabilization of synaptic 
activity following persistent deviation from an innate baseline level or “set-point,” is 
hypothesized to retain efficient information transfer capabilities in neurons by 
maintaining a dynamic range which encompasses the steady-state baseline activity (32, 
33). The homeostatic process may then subsequently allow for acute variation in activity 
upon demand, for example, during memory induction. The functional activity of neurons, 
in this case action potential output, appears under constant internal modulation around 
a point of reference. This set-point is hypothesized to result from the summation of 
intrinsic parameters including cell size and morphology as well as the complement and 
subunit composition/individual conductances of various ion channels (34). Existence of 
a or multiple sensors to monitor cell electrical state is therefore assumed, by which 
detection of out-of-range electrical activity triggers responsive mechanisms. This 
feedback control is a hallmark of homeostatic regulation and the subject of intensive 
research, primarily in relation to cell-intrinsic excitability, presynaptic release, and 
postsynaptic reception. 
Originally identified in electrophysiological studies of cultured neurons, so-called 
synaptic scaling was observed to occur following extended pharmacological up- or 
down-regulation of neuronal activity (35). Persistent voltage-gated sodium or GABAA 
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channel blockade decreased and increased neuronal activity, respectively. What is now 
recognized as homeostatic plasticity induction then occurred, whereby the postsynaptic 
cell increased or decreased its reception capabilities accordingly and reestablished 
intrinsic activity. These types of studies are still used in evaluating the mechanistic 
underpinnings responsible for resumption of baseline activity. Experimental approaches 
have also since expanded in scope to explore bidirectional contributions, that is, the 
pre-to-post anterograde signaling and post-to-pre retrograde signaling mechanisms 
involved. At mammalian central synapses the two main components hypothesized to 
facilitate homeostatic induction are presynaptic action potentials and protein translation. 
Depending on the system, homeostatic regulation is also now known to include effects 
on DNA transcription, protein translation, receptor trafficking, presynaptic release 
probability, and post-translational modifications, and may even be differentially enacted 
in individual synapses or classes of synapses within a single neuron (36). It is important 
to note that Hebbian and homeostatic forms of plasticity operate concurrently and are 
thought to exert influence over each other, though their timescales can vary (37, 38). 
Growing evidence suggests that induction of one form may shift the probability of future 
induction of the other. This interplay between Hebbian and homeostatic plasticities, 
maintaining cell adaptability while stabilizing intrinsic activity, is an area of intense 
investigation termed metaplasticity (39). 
 
Mechanisms of plasticity induction 
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Hebbian and homeostatic plasticity have been extensively examined through a 
reductionistic lens to gain insights into their cellular and molecular mechanisms (40, 41). 
Notable findings from these studies have identified numerous specific proteins, distinct 
morphological domains, and critical cell biological processes which are required or 
substantially impact plasticity induction and maintenance. Many of these mechanisms 
regulate both Hebbian and homeostatic plasticity, however key differences will likely be 
identified upon more nuanced experimental design in combination with higher precision 
research tools, such as genetic targeting of light-activated ion channels and specific 
microRNA and small-molecule-mediated inhibition of target substrates. 
Regulation of presynaptic terminal physiology allows for alterations in NT release 
through multiple mechanisms. The small GTPase Rab3, in addition to crucial effector 
proteins Rab3GAP and RIM1α, have been shown to influence both Hebbian induction in 
mice (42) and homeostatic induction in Drosophila (43). Because RIM1 anchors calcium 
channels in close proximity to the AZ, and is an effector of Rab3 and its activating 
protein Rab3GAP, which affects SV allocation into/out of the RRP, pool sizes and their 
related release probability are likely important and currently unappreciated methods of 
plasticity induction. However, it is at present unclear which homeostatic mechanisms 
identified at the Drosophila NMJ will be recapitulated with those of mammalian 
excitatory neurons of the CNS. Relatedly, the microRNA known as miR-458 targets the 
vesicle protein SV2A in the presynaptic downregulation induced by prolonged increases 
in activity in dissociated hippocampal culture (44). SV2A is reportedly important for 
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spontaneous vesicle release from these neurons and has been shown to indirectly 
influence postsynaptic spine density through this presynaptic mechanism. 
Postsynaptic mechanisms are more thoroughly-defined in the context of 
excitatory synaptic plasticity. The abundance of AMPARs in postsynaptic spines, the 
direct receivers of presynaptic input from across the synaptic cleft, is controlled via their 
insertion into or removal from the postsynaptic density (24, 45). The scaling of synaptic 
strength following homeostatic challenge has been examined in this context, indicating 
some overlapping AMPAR-related mechanisms as compared with Hebbian induction 
(46, 47). AMPAR-mediated changes in postsynaptic signal reception are partially 
controlled by the immediate early gene Arc/Arg3.1, which is involved in the structural 
and physiological competence of postsynaptic dendritic spines (48) and influences both 
Hebbian and homeostatic plasticity. Postsynaptic depolarization also repels pore-
blocking Mg2+ ions from NMDAR channels, increasing Ca2+ influx and the internal 
[Ca2+], which is often required for LTD and LTP induction. However, there is some 
question as to what extent LTD strictly requires an increase in postsynaptic calcium 
concentration (169). Furthermore, NMDAR activation upregulates the activity of the 
abundant kinases PKA, PKC, and CaMKII, triggering the phosphorylation of AMPAR 
reserves and their insertion into the postsynaptic membrane (49, 50), in addition to 
influencing their gating and ultimately modulating its intrinsic excitability. A growing body 
of evidence also highlights the importance of a retrograde signaling molecule, brain 
derived neurotrophic factor (BDNF), which is prompted by the mechanistic target of 
rapamycin complex 1 (mTORC1) upon post-synaptic inactivation to induce its local and 
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rapid translation within postsynaptic dendrites, functionally serving as a retrograde 
signal to induce compensatory increases in presynaptic function (51-53). It is presently 
unclear via what presynaptic mechanism compensatory changes are enacted, though 
the post-translational ubiquitination of proteins including AMPAR subunits within the 
postsynaptic cell appear important for sustained homeostatic plasticity in the same 
mammalian hippocampal culture system (54). 
The post-translational modification of protein substrates, such as ubiquitination 
and phosphorylation, in both pre- and post-synaptic compartments is indeed an integral 
layer of control in the establishment of Hebbian and homeostatic plasticity. Action 
potentials in the presynaptic neuron trigger the cAMP-dependent protein kinases PKA 
and PKC, which in turn respond to elevated calcium concentrations and phosphorylate 
major potassium channels, reducing the rate of membrane repolarization, and other 
molecular mediators in the exocytotic pathway to enhance glutamate release. 
Presynaptic PKA is also retrotranslocated to the nucleus, where it activates the 
transcription factor cAMP response element binding protein-1 (CREB-1) to upregulate 
protein synthesis and form new synapses. Furthermore, ubiquitin and ubiquitin-like 
modifiers (ULMs, also known as ubiquitin-like proteins (ULPs)) such as the small 
ubiquitin-like modifier (SUMO) and NEDD8 proteins are critical in the maintenance of 
cellular and synaptic physiology (55-60). Ubiquitin modifications are specifically 
important for the targeted regulation of protein levels, as will be described in detail in the 
following section. 
 
1.3 A molecular lifetime: Regulated protein turnover in neurons 
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An extensive literature has focused on the control of protein production and 
degradation mechanisms and their physiological impact on the development, health, 
and plasticity demands of the nervous system. Protein homeostasis (proteostasis) is a 
fine balance between two complementary systems which, together, continuously adjust 
the production and degradation of proteins within the cell. The functional result of these 
complex and coupled regulatory networks is the capability to, both globally and locally, 
preserve the neuronal proteome in a state which meets the current and/or future 
functional demands of the neuron. 
As it is central to the hypothesis of this dissertation, we now focus attention on 
regulatory mechanisms in neurons related to the turnover of synaptic proteins. Most 
intracellular proteins are subject to regulated degradation, which can occur on the 
timescale of minutes, to decrease their levels in a rapid and robust fashion even during 
continued production of new proteins. The mechanistic understanding of how targeted 
protein degradation influences their turnover rate and subsequently their abundance 
has advanced quickly. However, how the regulation of proteostasis via degradation 
directly impacts downstream neuronal physiology and plasticity, especially in 
consideration of the synapse, is of significant importance. 
 
Degradative and proteolytic systems 
 Proteolysis, or the inactivation and enzymatic breakdown of protein and peptide 
substrates into their constituent amino acid components, is mediated by a variety of 
proteases which together comprise multiple regulated degradative pathways. Just as 
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substrate protein populations vary enormously in composition, size, conformation, 
abundance, subcellular location, and function, the proteases which control their 
degradation are diverse. The two primary proteolytic systems in eukaryotic cells are the 
autophagy-lysosome system and the ubiquitin-proteasome system. Both govern protein 
degradation alongside synthesis to set and maintain the level of proteins within the cell. 
The UPS appears to regulate 80-90% of all intracellular proteolysis (61), while 
autophagy is responsible for approximately 10-20% (62, 63), though cell-type and state 
influence their activities. Autophagy and the UPS act concurrently and both operate 
using the ubiquitin molecule and ubiquitin-binding domains (UBDs) toward regulated 
protein degradation. However, autophagy and the UPS are distinct in their mechanism 
of proteolysis, ultimately operating as unique processes. The autophagy and lysosomal 
degradation of proteins is primarily a bulk mechanism through microautophagic 
invagination of the lysosomal membrane and cytoplasmic constituents, though substrate 
delivery to the lysosome can occur via chaperoning (64). During conditions of cellular 
stress, such as starvation, the cell may also utilize macroautophagy, whereby non-
cytosolic components such as mitochondria and the endoplasmic reticulum (ER) are 
engulfed into lysosomes. In contrast, the UPS affords more selective targeting of 
substrates for degradation, including specifically those which are over-abundant, 
misfolded, aggregated, or otherwise detrimental to the cell (63). 
Though the UPS operates in a dynamic fashion, its activity is strictly governed by 
a functional class of enzymes which act in series and parallel to identify, tag, target, and 
degrade the majority of intracellular proteins. As such, these UPS components serve as 
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a “chemical barrier” between active proteases and proteins of the cytosol, a mechanism 
utilizing specific targeting rather than a physical barrier, such as the membrane 
separating the acidic and protease-rich internal environment of the lysosome lumen 
from the protein-containing cytosol. Work in reticulocytes, maturing red blood cells 
which have expelled their lysosomes, allowed for the controlled examination of non-
lysosomal degradative pathways, as it was noted that reticulocytes have the capacity to 
rapidly and specifically degrade mutated or unassembled hemoglobins (65). This 
process was later shown to occur in an ATP-dependent manner, and most effectively at 
a neutral pH (66). This work indicated that non-lysosomal cellular activity was likely 
responsible for the selective degradation of proteins, which helped to explain the 
extensive variation (minutes to days) in protein half-lives observed by many cell 
biologists and biochemists. 
Some of the first evidence substantiating selective protein degradation in 
mammals was discovered by Rose, Hershko, and colleagues in the late 1970s, which 
challenged the pervasive assumption that most intracellular proteins were long-lived 
and degraded by the lysosome (67). These studies built upon observations in 
prokaryotes and eukaryotes from the previous three decades, primarily regarding the 
growing consensus that proteins operate in a dynamic state as a result of their 
synthesis and degradation rates. Seminal work in identifying the nature of regulated 
degradation was carried out by Aaron Ciechanover, as a graduate student in the lab of 
Avram Hershko, at the Technion Institute in Israel in 1978. The main conclusion of this 
early work was that proteolysis is not carried out by a single protease, but rather 
	 20	
multiple components which were differentially purified from rabbit reticulocytes (68). 
This group went on to further discover a small, heat-stable, 76 amino acid protein was 
covalently conjugated to protein substrates prior to an ATP-dependent process of 
degradation (69, 70). This ATP-dependent Proteolytic Factor 1 (APF1) was soon 
identified to be ubiquitin, whose covalent attachment necessarily preceded the ATP-
dependent proteolysis of many proteins. It was concluded that the addition of ubiquitin 
to a substrate protein acted as a “tag”, often marking the protein for degradation. This 
conclusion added a layer of potential specificity to the then-current models of proteolysis 
in that it afforded a reversible and specific mechanism (ubiquitination) to the irreversible 
and non-specific (proteolytic scission) framework already in place (71). This early work 
provided further valid evidence supporting an explanation for how both the mediators 
and targets of proteolysis coexist and are operable within the same cell compartment of 
the bulk cytosol in that it comprised a selective barrier. The post-translational 
modification of protein substrates by covalent addition of ubiquitin molecules and their 
subsequent degradation by the proteasome, well-known now as the Ubiquitin-
Proteasome System (UPS) or the Ubiquitin-Proteasome Pathway (UPP), has since 
been extensively studied. Furthermore, the foundational research, discovery, and 
examination of the mechanisms and functions of the UPS by Hershko, Ciechanover, 
and Rose was awarded the Nobel Prize in Chemistry in 2004. 
 
Introduction to the Ubiquitin-Proteasome System 
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The UPS is a selective degradation system utilizing the small molecule termed 
ubiquitin, named as such because it was found to be expressed in all eukaryotes prior 
to the identification of its function. Many detailed reviews of the general (67, 72-76) and 
nervous system-specific (77-82) mechanisms and effects of protein ubiquitination and 
degradation by the UPS exist, and what follows is a brief summary of the current views 
on this process, with selected findings highlighted based on specific relevance. The 
substrate selectivity of the system results from its multistep utilization of enzymes and 
cofactors, commonly referred to as the “enzymatic cascade”. The covalent attachment 
of a ubiquitin moiety to its target substrate is most commonly termed ubiquitination, but 
also ubiquitylation, and requires upstream activation and downstream handling of the 
ubiquitin small molecule. The cooperation of three classes of enzymes are primarily 
responsible for substrate ubiquitination, generally known as ubiquitin-activating 
enzymes (E1s), ubiquitin-conjugating enzymes (or ubiquitin-transferring enzymes, E2s), 
and ubiquitin ligases (E3s). These components, and their various identity-specific 
interdependencies, afford further fine-tuning of substrate selectivity throughout the 
process. Ubiquitination of a protein with the ultimate intent of degradation often occurs 
at specifically targeted lysine residues via stereotyped multi-ubiquitin linkages and poly-
ubiquitin chains. Using poly-ubiquitin chains as molecular tags, the cell targets the 
protein for recognition and proteolysis by the large, multi-subunit complex known as the 
26S proteasome, whereby the substrate is cleaved into short poly-peptides of between 
3-32 amino acids in length and the ubiquitin molecules are recycled for further use. 
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Following cellular identification of protein substrates for degradation, including 
those which are terminally misfolded, aggregated, non-functional, and/or damaged, 
ubiquitination and chaperones are employed for initiation of the UPS toward rectifying 
the imbalance (83). The ubiquitin molecule is first activated by an E1 through the use of 
ATP to form ubiquitin adenylate. The ubiquitin molecule is then transferred to an E2 via 
a thioester bond and prepared for handling alongside an E3. Some E2s directly link 
ubiquitin to the target protein with or without recruitment of an E3 as a substrate-
selective adaptor. In other cases, an E3-ubiquitin thioester intermediate is formed prior 
to the transfer of ubiquitin from the E2 to the E3, again utilizing the E3 for substrate 
specificity (72). Each step in this cascade provides for further substrate selectivity and 
accuracy, as some E3s have varying affinities for different individual or classes of 
upstream E2s as well as downstream protein substrates. For example, UbcH8, a human 
E2, interacts with parkin and E6-AP, whereas a similar E2, UbcH5, functions specifically 
with Rsp5 and BRCA1-BARD1 (84). The honing of substrate specificity is finer at the 
single protein scale, which have canonical lysine residues which are ubiquitinated under 
certain conditions and by the action of particular E2-E3 combinations. Amino acid sites 
of ubiquitination, especially in cases where ubiquitination leads to protein degradation, 
are overwhelmingly lysines, but also occasionally a serine, threonine, or cysteine (85). A 
notable example of regulated degradation following ubiquitination of a protein substrate 
at specific lysine residues occurs by the E3 ligase known as neural precursor cell 
expressed developmentally down-regulated 4 (Nedd4), which ubiquitinates neuronal 
glutamate receptors, specifically Lysine-868 of the AMPA-type glutamate receptor 
	 23	
subunit 1 (GluA1) C-terminus, which results in receptor internalization and degradation 
(86). After initial ubiquitination of a protein substrate, additional ubiquitin moieties can be 
added to any number of the seven lysine residues of ubiquitin, beginning a poly-
ubiquitin chain. Chain elongation primarily occurs via the iterative addition of additional 
ubiquitin molecules to those which are already linked which, dependent upon the poly-
ubiquitin chain structure and length, determines the substrate’s fate. 
Poly-ubiquitinated proteins, specifically those with multi-ubiquitin chains of K48 
and K63 ubiquitin linkages, are then degraded by the 26S proteasome complex. The 
26S proteasome contains a catalytically active, cylindrical 20S core apposed on each 
end by a 19S regulatory particle (87). Molecular catabolism of poly-ubiquitinated 
proteins occurs by the central 20S core. The 20S core is comprised of two outer rings, 
each with seven alpha subunits and two inner rings, each with seven beta subunits, 
three of which (ß1, ß2, and ß5) are required for its catalytic activity. Unfolded substrates 
are recognized by the 19S regulatory particle and passed through a pore of roughly 13 
ångström diameter (88), which is size-restrictive for all but unfolded substrates, into the 
catalytic core. Evidence most strongly supports protein unfolding is accomplished by 
19S ATPases, comprised of six regulatory ATPase subunits (Rpt 1-6) in addition to four 
non-ATPase subunits (Rpn 1, 2, 10, and 13) (89). Usp14 (or Ubp6) has been shown to 
reversibly associate with Rpn1 to initiate protein degradation via deubiquitination (90, 
91). The poly-ubiquitin chains themselves are not cleaved, but detached and 
disassembled by one of two classes of deubiquitinating enzymes (DUBs). DUBs are 
most commonly differentiated by their size and contain varying intrinsic substrate 
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specificities. Low molecular weight DUBs are also known as ubiquitin C-terminal 
hydrolases (UCHs), conversely, high molecular weight DUBs are termed ubiquitin-
specific proteases (USPs, or UBPs) (84). The lid of the 19S regulatory particle contains 
nine non-ATPase subunits (Rpn3, 5, 6-9, 11, and 15) (92) and has shown 
deubiquitinase activity by Rpn11 (Poh1) and 13 (Uch37) during substrate unfolding and 
insertion into the catalytic chamber through the pore. Furthermore, the proteasome 
complex is itself subject to post-translational modification in regulation of its activity, 
including phosphorylation (93). 
 
E3 ubiquitin ligases and target specification of the UPS  
 The dynamic regulation of cellular function requires targeting of specific protein 
substrates for ubiquitination and subsequent degradation. Substrate specificity is 
primarily implemented via a diverse population of E3 ubiquitin ligases. Neuronal E3s are 
expressed throughout the cell and localize to the nucleus, golgi apparatus, endoplasmic 
reticulum (ER), dendrites, axons, and synapses. Their subcellular localization is thought 
to contribute to the recognition of and reaction to intrinsic and extrinsic cues, in some 
cases allowing for local and rapid regulation. E3s, like other examples of post-
translational protein modification, regulate many aspects of cellular physiology, 
including proper cell proliferation and differentiation, gene expression and DNA repair, 
apoptosis (81), and importantly, neuronal morphology and synaptic activity and plasticity 
(77, 79). 
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E3s can function individually or in protein complexes and either as an 
intermediate substrate, itself directly catalyzing ubiquitin transfer to the target after 
accepting it from an E2, or by bringing together an E2-ubiquitin conjugate and its target. 
The over 800 E3s encoded by the human genome can be categorized into two large 
classes, which are differentiated by their catalytic domains, and therefore their 
mechanisms of ubiquitination and degradative control (94). The former, intermediate 
acting group are termed HECT domain ligases (for homologous to E6-AP carboxyl-
terminus), and the latter, E2-to-substrate paring group are known as RING finger 
ligases (for really interesting new gene). The RING finger E3s alone are represented by 
over 600 gene products in humans (95), denoting their potential for high target 
specification in directing protein ubiquitination. Later identified was a third class of E3s 
with the so-called U-box domain, also referred to as E4s in that they provide ubiquitin 
chain elongation (96), though these are more often considered to be modified RING-
finger domains. Six of these factors were originally identified to be capable of catalyzing 
the ubiquitination of mammalian substrates with dependence on E1 and various E2s but 
in the absence of any HECT- or RING-type E3 (97, 98), further implying they have E3 
activity. In addition to the extensive number of identified and predicted E3s, many 
studies have implied further intrinsic E3 specificity results from the distinct subcellular 
localizations of many E3s throughout neuronal and synaptic development, maturation, 
and maintenance (81). 
 
Neuronal and synaptic effects of the UPS 
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It is recognized that E3 ubiquitin ligases are especially important in the function 
of neuronal cells and signaling, and extensive evidence indicates this includes 
perturbed physiology and disease states in addition to normal function. For example, 
HECT domain E3s were discovered to be a class of ubiquitin ligases with a homologous 
C-terminal region to E6-AP (known as UBE3A in humans), which ubiquitinates the 
tumor suppressor protein p53 in HPV-infected cells (99) and when defective in humans, 
causes the neurodevelopmental disorder termed Angelman Syndrome. Patients 
suffering from Angelman syndrome display severe intellectual disabilities beginning in 
early development (100, 101), and a mouse model of the disease shows impaired LTP 
and spatial learning (102) likely due to synaptic ubiquitination of the AMPAR 
endocytosis and plasticity-related protein Arc (activity-regulated cytoskeleton-associated 
protein, also known as Arg3.1) (103). RING finger domain E3s can be sub-divided into 
two classes, based on their containing either a single subunit, for example Mdm2 (for 
mouse double minute 2), or multiple subunits, such as APC (for anaphase-promoting 
complex, also known as cyclosome and APC/C). Mdm2 is known to ubiquitinate the 
synaptic scaffolding protein PSD95 (104) to influence signal reception, and APC plays 
an important role in the differentiation (105) and size (106) of presynaptic sites, in 
addition to dendrite morphogenesis (107). 
 As previously mentioned, the UPS regulates the activity of critical neuronal cell 
systems, for example, the abundance of PKA regulatory subunits. However, there is 
also a wealth of evidence indicating more acute control of neuronal proteins which 
directly influence their neuronal function and activity. The degradation of presynaptic 
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components is the topic of intensive study, as this process can regulate 
neurotransmitter release and plasticity. For example, the presynaptic vesicle associated 
proteins RIM1α and syntaxin1, which are both critically important in neurotransmitter 
release, are known targets for proteasomal degradation (108, 109). Syntaxin1 is 
specifically targeted for ubiquitination by the E3 ligase staring, though its physiological 
significance in living neurons has yet to be evaluated. Additionally, the E3 known as 
SCRAPPER was shown to regulate the levels of the presynaptic scaffolding protein 
RIM1α to modulate synaptic transmission by modulating release probability, as 
measured by miniature excitatory postsynaptic currents (mEPSCs) in culture, and also 
affecting short-term plasticity in mice (108). It is furthermore hypothesized that activity of 
the proteasome contributes to the maintenance of synaptic vesicle pools, as their 
inhibition increases the recycling pool size but not neurotransmitter release probability in 
cultured neurons (110). This effect was occluded by concurrent pharmacological 
neuronal activity blockade. Proteasome blockade also increased mEPSC frequency, but 
not amplitude, indicating an importance for the presynaptic terminal to maintain proper 
proteostasis via proteasomal degradation in mammalian hippocampal neuronal culture 
(111). Relatedly, Dunc-13, the drosophila ortholog of mammalian Munc-13, a 
presynaptic priming protein, is degraded by the proteasome to control the number and 
output of presynaptic terminals at the drosophila neuromuscular junction (112). It is 
unclear under what circumstances or physiological states cue the degradation or 
stabilization of key presynaptic proteins. However, these notable examples of UPS-
mediated control over the abundance of crucial proteins involved in presynaptic 
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physiology indicate the importance of further examining this system for a more 
comprehensive understanding of changes in protein homeostasis that may affect 
synaptic morphology, number, and/or function. 
 There is also significant evidence indicating the degradative regulation of 
postsynaptic protein levels by the UPS, primarily regarding the regulation of 
neurotransmitter receptors and related scaffolding proteins (113). Ubiquitination of 
membrane receptors, most frequently via K63 linkage types, often leads to their 
internalization and ultimately either; recycling and reinsertion into the postsynaptic 
membrane following deubiquitination by DUBS (114), sorting and degradation by the 
lysosome (77), or degradation by the proteasome (72). Simple inhibition of proteasome-
mediated degradation via pharmacological blockade in cultured hippocampal neurons 
indicates an overall decrease in AMPAR internalization (115). Additionally, the 
postsynaptic scaffolding protein PSD95 is subject to degradation prompted by the UPS, 
which itself leads to AMPAR internalization (104). Slice culture experiments from the 
same study indicated a decrease in LTD following pharmacological proteasome 
blockade. UPS control over postsynaptic physiology and plasticity is not limited to 
excitatory systems, as GABA (116) and Glycine (117) receptors are also ubiquitinated, 
internalized, and degraded by the proteasome. Further study into the activity states and 
cell biological pathways underlying regulated protein turnover in neurons is paramount 
to a more comprehensive understanding of how the UPS influences neuronal and 
synaptic physiology. 
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Regulatory actions of the RING-type E3 ubiquitin ligase HRD1 
One mechanism by which neurons, as well as other cell types, regulate 
misfolded, mutated, or perturbed protein expression levels is via ER-associated 
degradation (ERAD). ERAD is the crucial process whereby targeted ER, secretory, and 
related proteins are retro-translocated through the membrane into the cytosol prior to 
their deubiquitination and degradation by the proteasome. Disturbances in ER protein 
homeostasis cause ER stress, which activates the unfolded protein response (UPR) to 
alter the expression of many genes involved in ER quality control. One of those 
upregulated genes encodes an important RING-type E3 termed HRD1 (also known as 
Hrd1p, Der3p, and synoviolin), an ER-resident, transmembrane ubiquitin ligase required 
for ERAD (118). HRD1 serves as the central component of the large, multi-protein 
complex that facilitates the degradation of ERAD substrates, which are most often 
misfolded, damaged, or aggregated. Cryoelectron microscopy data support that HRD1 
creates an ER-transmembrane pore, likely acting as a protein channel, in complex with 
the related HRD3 (119). This channel formation may be prompted by HRD1 auto-
ubiquitination (120), though a lack of HRD3 is also hypothesized to cause unrestricted 
self-degradation of HRD1 (121). The catalytic ligase activity of HRD1 emerges from its 
various interdependent subunits and domains. HRD1 is comprised of an eight-spanning 
transmembrane domain, a cytosolic RING-finger domain, and an evolutionarily 
conserved but intrinsically disordered HAF-H domain, which engages co-factors in the 
cytosol (122). 
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The HRD1-containing complex also contains SEL1L, which is stabilized by 
HRD1, whose transmembrane domain may regulate HRD1 function (123). Relatedly, 
OS-9, a lectin responsible for binding terminally misfolded non-glycosylated proteins 
and improperly folded glycoproteins, is hypothesized to retain its targets at the ER and 
transfer them to the HRD1 ubiquitination machinery (124-127). Recently, two major 
high-molecular-mass complexes containing HRD1 were identified, each with distinct 
interacting proteins and variable stoichiometries, indicating heterogeneity in the 
functional units of HRD1-mediated protein degradation (128). The composition and 
stoichiometry of HRD1-containing complexes are heavily influenced by HRD1 
expression levels. As such, HRD1 is itself strictly regulated within the cell. It is a 
substrate for the DUB known as ubiquitin-specific protease 19 (USP19), which 
deubiquitinates HRD1 and promotes its stabilization by inhibiting degradation (129). 
HRD1 is also targeted for degradation by the related E3 GP78 (130). 
HRD1 has been shown to specifically ubiquitinate dozens of proteins (131), often 
having anti-aggregation effects on proteins and an overall anti-apoptotic effect on the 
cell. Importantly, while HRD1 is well-recognized for regulating biosynthetically ER-
targeted proteins, it has also more recently been reported to regulate several cytosolic 
proteins, presumably due to cytosolic capture and delivery. These include the tumor 
suppressor protein p53 (132, 133) and optineurin (134), a cytosolic protein involved in 
the maintenance of the Golgi complex, membrane trafficking, and exocytosis in 
neuronal cells (135). Furthermore, ER stress causes the aggregation of proteins, most 
of which are not ER or secretory pathway proteins. Proteomic analysis of aggregated 
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proteins has revealed enrichment of intrinsically aggregation-prone proteins, rather than 
those which are affected in a stress-specific manner (136). 
HRD1 has several reported regulatory actions that are likely functionally 
important in neurons. The upregulation of HRD1 expression resulting from ER stress 
inhibits neurite outgrowth and dendritic arborization in differentiated neurons, and 
knockdown (KD) of HRD1 abolished these effects (137). Relatedly, HRD1 facilitates the 
degradation of components of the synaptic proteome, including the Parkin-associated 
endothelin receptor-like receptor PaelR (138), and tau and p-tau to promote neuronal 
survival by inhibiting protein aggregation (139). HRD1 can also target pathogenic poly-
glutamine expanded huntingtin protein (httN) for degradation, thereby protecting cells 
against httN-induced cell death (140). Taken together, these findings highlight the 
potential for HRD1-mediated control of protein turnover as a critical mechanism of 
neuronal and synaptic physiology. 
 
Preview to the dissertation: Tomosyn as a prime target for mediating UPS-dependent 
synaptic plasticity 
Activity-dependent alteration of the structure and activity of synapses linking 
neurons into functional networks is foundational to their capacity for encoding, storing, 
and relaying information. A balance of local de novo protein synthesis and targeted 
protein degradation within these synapses promotes long-lasting changes in synaptic 
efficacy that are maintained well-beyond the induction period (77, 141-143). For 
example, the mTORC1 signaling pathway is induced in postsynaptic dendrites in an 
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activity-dependent fashion to regulate protein translation (144) and mediate the long-
lasting plasticity required for some forms of learning/memory (145, 146) and synaptic 
adaptations (52, 147). Downstream effects mediate a retrograde signal to retune 
neurotransmitter release and reception through an unidentified mechanism which is 
partially dependent upon activity of the proteasome via UPS-mediated degradation (54). 
The central hypothesis of this dissertation is that a synaptic molecular 
mechanism underlying neuronal plasticity is Tomo-1. Furthermore, we hypothesize that 
this plasticity may result from currently unidentified postsynaptic actions of Tomo-1 
following the specific upregulation of Tomo-1 ubiquitination by HRD1 and subsequent 
proteasomal degradation (see Fig. 1.1). In examination of this hypothesis I test for 
downstream effects of the newly-identified regulation of Tomo-1 proteostasis by HRD1, 
including consequential synaptic morphology. Testing this hypothesis allows for 
significant advancement of the understanding of a central mechanism by which pre- and 
post-synaptic terminals are functionally integrated and cooperatively implement locally-
mediated plasticity. Further informing our comprehension of this process will 
significantly advance the field by contributing novel mechanistic insight into the 
molecular underpinnings of these coordinated, trans-synaptic pathways. 
Notably, Tomosyn proteins are also correlated with neurological disorders 
including as autism spectrum disorder (ASD), intellectual disability, and epilepsy (151-
153). Tomosyn proteins are encoded by two genes in mammals, Tomosyn-1 and 
Tomosyn-2, and differentially spliced into seven protein isoforms (154). They are 
generally considered to be inhibitors of membrane fusion, specifically, evoked vesicle 
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fusion from neurons and neuroendocrine cells. Indeed, overexpression of Tomo-1 in 
neuronal cells leads to reduced membrane fusion and secretion (155-158). The 
prevailing mechanistic model of Tomo-1’s inhibitory actions on membrane fusion 
postulates that its C-terminal, VAMP-like R-SNARE domain competitively inhibits the 
interaction of VAMP2 and Munc18 with Syntaxin1A (161, 162). Thus, this model 
proposes Tomosyn functions as a clamp on fusion events via action of its SNARE 
domain. Another mechanism by which Tomo-1 may negatively regulate fusion has also 
been identified to result from its N-terminal ß-propeller domains (156, 157, 163-166). 
These highly structured regions are hypothesized to contribute in reallocating vesicles 
into a non-releasable pool to decrease or abolish the induction of some forms of 
synaptic plasticity and memory (158, 167, 168). Additionally, previous work from our lab 
identified two of the three unstructured loop domains (loop numbers one and three, but 
not two) emanating from the ß-propeller core of mammalian Tomo-1 to be crucial for its 
inhibition, but not its binding with Syntxain1A (166). Lastly, PTM of Tomo-1 by the small 
ubiquitin-like modifier SUMO2/3 within loop number two enhanced its inhibitory actions 
without affecting its Syntaxin1A binding characteristics. Therefore, the negative 
regulation of membrane fusion by Tomo-1 is not entirely imposed by its SNARE domain 
via competitive inhibition of Syntaxin1A binding. Further examination of Tomo-1-
dependent effects on synaptic morphology and physiology is needed to elucidate the 
mechanistic contributions post-translational modifications of Tomo-1 at specific regions 
to its actions on membrane trafficking/fusion. 
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Figure 1.1: General hypothesis model. 
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Figure 1.1: General hypothesis model. 
 
A simplified cartoon model outlining our hypothesis that a synaptic molecular 
mechanism modulating the information encoding capabilities between neurons is the 
UPS-dependent, specific regulation of Tomo-1 ubiquitination by HRD1 and its 
subsequent proteasomal degradation. Furthermore, we expect novel neuronal plasticity 
effects may result from currently unidentified postsynaptic actions of Tomo-1 protein, 
such as on dendritic spine morphology or number.	 	
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CHAPTER II 
The ubiquitin-proteasome system functionally links neuronal Tomosyn-1 to 
dendritic morphology 
 
2.1 Abstract 
 Altering the expression of Tomosyn-1 (Tomo-1), a soluble, R-SNARE domain-
containing protein, significantly affects behavior in mice, Drosophila, and Caenorhabditis 
elegans. Yet, the mechanisms modulating Tomo-1 expression and its regulatory activity 
remain poorly defined. We found that Tomo-1 expression levels influence postsynaptic 
spine density. Tomo-1 overexpression increased dendritic spine density, while Tomo-1 
knockdown (KD) decreased spine density. These findings identified a novel action of 
Tomo-1 on dendritic spines, which is unique because it occurs independently of Tomo-
1’s C-terminal R-SNARE domain. We also demonstrated that the ubiquitin-proteasome 
system (UPS), which is known to influence synaptic strength, dynamically regulates 
Tomo-1 protein levels. Immunoprecipitated and affinity-purified Tomo-1 from cultured rat 
hippocampal neurons was ubiquitinated, and the levels of ubiquitinated Tomo-1 
dramatically increased upon pharmacological proteasome blockade. Moreover, Tomo-1 
ubiquitination appeared to be mediated through an interaction with the E3 ubiquitin 
ligase HRD1, as immunoprecipitation of Tomo-1 from neurons co-precipitated HRD1, 
and this interaction increases upon proteasome inhibition. Furthermore, in vitro 
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reactions indicated direct, HRD1 concentration-dependent Tomo-1 ubiquitination. We 
also noted that the UPS regulates both Tomo-1 expression and functional output, as 
HRD1 KD in hippocampal neurons increased Tomo-1 protein level and dendritic spine 
density. Notably, the effect of HRD1 KD on spine density was mitigated by additional 
KD of Tomo-1, indicating a direct HRD1/Tomo-1 effector relationship. In summary, our 
results indicate that the UPS is likely to participate in tuning synaptic efficacy and spine 
dynamics by precise regulation of neuronal Tomo-1 levels. 
 
2.2 Introduction 
Synaptic structure and activity within the central nervous system are continually 
modified as the result of ongoing cognitive, affective, motor, and environmental 
experiences. Manifestations of this plasticity, while diverse in mechanism, are largely 
composed of dynamic changes in the molecular regulation of synaptic efficacy, intrinsic 
electrical properties, and/or cell morphology. While activity-dependent regulation of the 
synaptic proteome via de novo translation has long been recognized (1, 2), it was not 
until the 1990s that the role of the ubiquitin-proteasome system (UPS) began to be 
appreciated in targeted degradation of proteins participating in synaptic plasticity (3). 
Accumulating evidence has now established a key role for the UPS in regulating 
the development and efficacy of synapses (4-6). Acting within both pre- and post-
synaptic compartments, the UPS has been reported to control a number of specific 
actions, including: synapse maturation and maintenance, silencing presynaptic activity, 
and inhibiting the assembly of SNARE core complexes (7-10). The UPS also 
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determines the AMPA receptor content and functional state of the postsynaptic density 
(PSD) (11, 12), degrading neurotransmitter receptors and scaffolding proteins, in 
response to neural activity directing proteasomes to dendritic spines (13, 14). Moreover, 
extensive evidence implicates the UPS in regulating spine dynamics (15) and trans-
synaptic plasticity (16). Differential targeting of positive and negative regulators of 
synaptic plasticity by the UPS is therefore proposed to contribute to the physiological 
dynamic range of neurotransmitter release and reception, and hence, the efficacy of 
information transfer at synapses. 
Tomosyn-1 (Tomo-1) is a soluble, SNARE-family protein, primarily known as a 
potent negative regulator of vesicle fusion (17) that strongly reduces evoked exocytosis 
of neurotransmitter-containing vesicles (18-20) and plasticity induction within the brain 
(21-23). Though soluble, Tomo-1 also associates with secretory vesicles and plasma 
membranes in neuroendocrine cells (24, 25) and neurons (26-28). Tomo-1 has been 
observed to regulate neurite outgrowth and increase branching complexity in developing 
cultured rat hippocampal neurons and chemically-differentiated NG108 cells (29). 
Moreover, our recent study demonstrated an importance of Tomo-1 in modulating 
distribution of presynaptic vesicles among functionally defined vesicle pools, separating 
actively recycling vesicles from non-fusogenic resting vesicles (30). 
Highly conserved orthologs of Tomo-1 are found in S. cerevisiae (Sro7p/77p), C. 
elegans (TOM-1), and D. melanogaster (Lgl), where they appear to exhibit strong 
similarities in structural properties (31-35) and mechanistic actions (36-38). TOM-1 has 
been reported to participate in trans-synaptic plasticity via the neurexin-neuroligin 
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pathway in C. elegans (39). Tomo-1 is also critical for some forms of plasticity and 
memory, including hippocampal-dependent learning and memory in mice (22), and 
associative odor memory in D. melanogaster (21). These reports suggest the activity 
and functional impacts of Tomo-1 may be dynamically modifiable as a result of neural 
activity. 
Tomo-1 is subject to multiple forms of post-translational modification in neurons, 
including phosphorylation by PKA (36) and CDK5 (30), and SUMOylation (40) by PIASγ 
(41). While PKA phosphorylation at serine-724 and SUMOylation at lysine-730 both 
reduce the inhibitory actions of Tomo-1, they do so by different means, as only PKA 
phosphorylation reduces Tomo-1 interaction with the R-SNARE syntaxin-1a. By 
comparison, CDK5 phosphorylation of Tomo-1 has been reported to increase its 
inhibitory properties on membrane trafficking (30). Sro7p/77p also functionally regulate 
membrane vesicle trafficking with their activity subject to regulation by Rab-GTPases 
(Sec4) and a type V myosin (Myo2) (31). Like Tomo-1, the related Tomo-2 protein is 
also expressed within cytoplasm of neurons, including those within the hippocampus in 
mice (42). Interestingly, expression of Tomo-2 in HEK293T or the insulin-secreting INS1 
cell lines revealed it was a target of UPS-mediated degradation (43). However, the role 
of the UPS in regulating Tomo-1 level within neurons remains unknown. 
Characterizing processes determining Tomo-1 protein level and functional state 
is important based on Tomo-1’s key role in modulating vesicle release probability and 
trans-synaptic tuning in neurons. The purpose of the current study was to examine 
UPS-mediated regulation of Tomo-1 in hippocampal neurons and the impact of this 
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regulation on synaptic structure. In addition, SNARE-domain containing proteins, 
including Tomo-1, and the UPS have been linked to the proteinopathy and protein 
aggregation associated with neurological and neurodegenerative diseases; including 
Autism Spectrum Disorders (ASD) (44-46), Alzheimer’s Disease (AD) (47, 48) and 
Parkinson’s Disease (PD) (49, 50). Specifically, Tomo-1 gene variation in humans have 
been correlated with ASD (51). 
 
2.3 Results 
Tomo-1 Expression Level Alters Dendritic Spine Density 
As Tomo-1 is reported to alter membrane trafficking and vesicle fusion, we 
initially examined if Tomo-1 alters the density or morphology of dendritic spines in 
synaptically mature cultures of rat hippocampal neurons (17-24 DIV). Neurons were 
transfected with a soluble mCherry fluorophore (mCH), and co-transfected with one of 
the following expression constructs: 1) N-terminal tagged eGFP-m-Tomo-1 (Tomo-1), 2) 
eGFP-m-Tomo-1 containing a C-terminal R-SNARE motif deletion (ΔCT), 3) cytosolic 
eGFP, as a control for the overexpression of vectors containing eGFP (GFP), 4) shRNA 
targeting m-Tomo-1 for knockdown (KD), and 5) the same shRNA vector with a 
scrambled nucleotide sequence replacing the Tomo-1 target sequence (SCR). In 
addition, we examined a condition in which shRNA KD of rat Tomo-1 was rescued with 
co-transfection of shRNA-resistant human N-terminal tagged mCH-Tomo-1. 
Effectiveness of the Tomo-1 KD and rescue was confirmed by both 
immunocytochemistry (ICC, Fig. 2.1A-B, D) and Western blot (WB, Fig. 2.1C-D). ICCs 
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were quantified in transfected, shRNA-expressing neurons, relative to neighboring non-
transfected control neurons. High-resolution confocal imaging of neurons transfected 
with GFP-Tomo-1 also demonstrated localization within the cytosol to dendrites and 
spines (Fig. 2.2A). For spine analysis co-expression of mCH and either GFP-Tomo-1, or 
shRNA constructs also encoding GFP, was confirmed by imaging of both mCH and 
GFP spectral lines. WBs of lysates from virally-infected neuronal cultures demonstrated 
that our expression constructs successfully KD, overexpress, and rescue Tomo-1 in 
neurons (Fig. 2.1C-D). To restrict fluorescence analysis to processes arising from 
individual neurons, we transfected cultures under conditions generating low transfection 
efficiency (≈ 2-5 cells per coverslip). To assess alterations in dendritic spine density and 
morphology, transfected neurons were subjected to laser-scanning confocal microscopy 
(LSCM) of mCH fluorescence intensity over a series of Z-planes. Acquired Z-stacks 
were subsequently compiled to render 3-dimensional reconstructed dendrites from 
which spine density and morphology was quantified by following a single dendritic arbor 
projecting from each neuronal cell body. Representative images of dendrite segments 
for each condition tested are shown in Fig. 2.2B. 
Importantly, our results demonstrate that exogenous Tomo-1 expression 
specifically and significantly increased average spine density. In contrast, shRNA-
mediated KD decreased dendritic spine density, an effect overcome by Tomo-1 rescue, 
relative to respective controls (Fig. 2.2C). This identifies a novel postsynaptic function 
for Tomo-1, as the sparse transfection makes an indirect presynaptic effect unlikely. 
Notably, this effect occurred independently of Tomo-1’s C-terminal R-SNARE domain. 
	 58	
That is, the effects on spine density of Tomo-1 lacking its R-SNARE domain (ΔCT) were 
not significantly different from those overexpressing wild-type Tomo-1. Expression of 
the scrambled shRNA control sequence (SCR) had no significant effect on spine density 
relative to GFP control. Although Tomo-1 overexpression and knockdown was found to 
affect spine density, no significant effects were found on total spine length (Fig. 2.2D), 
spine head maximum diameter (Fig. 2.2E), or spine head volume (Fig. 2.2F). However, 
the rescue of Tomo-1 expression did indicate increases in maximum spine head 
diameter and volume (Fig. 2.2E-F, purple). Moreover, as shown in Fig. 2.2G-H, 
cumulative frequency distributions of dendrite spine count versus distance from 
neuronal soma confirmed statistically significant differences between Tomo-1, ΔCT, and 
KD relative to respective controls. Notably, the cumulative distributions were generally 
linear for each condition, indicating a uniform distribution of spine number over the 
measured distance of the dendrite. These results are the first to indicate Tomo-1 protein 
has the capacity to regulate the genesis or stability of dendritic spines, and potentially, 
the integrative synaptic drive of hippocampal neurons in culture. 
 
Endogenous Tomo-1 Colocalizes with PSD95 in Dendritic Spines 
Next, we examined by ICC if endogenous Tomo-1 is colocalized with the 
postsynaptic density protein PSD95, which may implicate its presence locally within 
spines of hippocampal neurons. Antigen specificity of the antibodies was confirmed by 
ICC of transfected HEK293T cells selectively overexpressing Tomo-1, Tomo-2, or 
empty vector control (Fig. 2.3A). Antibody specificity was further determined by WB of 
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transfected HEK293T cell lysates (Fig. 2.3B). As shown in Fig. 2.3C, ICC demonstrated 
that Tomo-1, while expressed throughout neurons, exhibits intense punctate 
immunofluorescence signals within neuronal processes. While several prior reports 
have noted that Tomo-1 colocalizes with presynaptic markers, our results reveal Tomo-
1 is also often found localized at postsynaptic sites, as indicated by colocalization of 
individual Tomo-1 and PSD95 immunofluorescent puncta (Fig. 2.3C, white arrowheads; 
Fig. 2.3D, top). Indeed, line profiles of immunofluorescence along straightened 
dendrites show sites with highly correlated enrichment of Tomo-1 and PSD95 (Fig. 
2.3D, bottom). Furthermore, pixel-by-pixel analysis of intensity profiles between the 
spectral channels further supports the validity of the observed colocalization between 
Tomo-1 and PSD95 (Fig. 2.3E, Pearson’s overlap coefficient; r=0.885, r2=0.783, 
Manders’ correlation coefficients; M1=0.759 (fraction of PSD95 overlapping Tomo-1), 
M2=0.889 (fraction of Tomo-1 overlapping PSD95)). 
 
Proteasomal Regulation of Tomo-1 Determines its Abundance 
As Tomo-1 expression level correlated with changes in dendritic spine density we 
next evaluated if the UPS may dynamically regulate neuronal Tomo-1 levels. First, we 
tested the effects of inhibiting the proteolytic activity of the 26S proteasome complex via 
bath application of MG132 (MG; 50μM, 4H) or Lactacystin (Lac; 10μM, 4H) vs. DMSO 
vehicle control. Proteasome blockade via either drug significantly increased neuronal 
Tomo-1 protein levels, as shown by WB analysis of whole-cell lysate (Input) samples 
(Fig. 2.4A, G). Proteasome inhibition demonstrated no significant effect on total β-actin 
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level. Depletion immunoprecipitation (IP) of Tomo-1 from lysate samples following 
proteasome blockade largely reproduced effects found on WB Input samples (Fig. 2.4B, 
H). Specificity of the anti-Tomo-1 antibody used for IP was verified, as no 
immunoreactivity was apparent in WB of rabbit IgG control or Tomo-2 IPs (Fig. 2.4C-D). 
 
Tomo-1 Interacts with the E3 Ubiquitin Ligase HRD1 in a Proteasome Activity-
dependent Fashion 
HRD1 is an E3 ubiquitin ligase integral in the endoplasmic reticulum (ER) 
membrane (52). It is known to inhibit apoptosis following buildup of misfolded proteins 
and ER stress (53) and it is critical for ER-associated degradation (ERAD) (54). HRD1 
protein is expressed in neurons, but not glia, of the hippocampus, dentate gyrus, and 
cerebral cortex (55), all of which also exhibit Tomo-1 protein expression (42, 56). 
Notably, HRD1 has previously been identified as an interacting partner of Tomo-2 in a 
proteomics screen of Tomo-2 IP from the INS1 pancreatic β-cell line, and was further 
reported to regulate Tomo-2 level when co-expressed in HEK293FT cells (43). 
Therefore, we next investigated if Tomo-1 interacts with HRD1 in hippocampal neurons, 
and if this is an E3-mediated mechanism by which Tomo-1 is specifically ubiquitinated 
and targeted for degradation. To test this, Tomo-1 was immunoprecipitated from 
neuronal lysates and the IP sample was tested for HRD1 co-precipitation. As shown in 
Fig. 2.4B, Tomo-1 IP resulted in co-precipitation of HRD1. As control, IP with anti-rabbit 
IgG, resulted in no Tomo-1 or HRD1 immunoreactivity (Fig. 2.4C). To date, most known 
Tomo-1 protein interactions have been reported to occur via its R-SNARE domain, 
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which is homologous to the R-SNARE of VAMP2. However, as shown in Fig. 2.4E, IP of 
VAMP2 from neuronal cultures failed to co-IP HRD1, indicating that the Tomo-1 SNARE 
motif is unlikely a domain essential for interaction between Tomo-1 and HRD1. Though 
the UPS inhibitors MG or Lac increased Tomo-1 level in neuronal cultures, no 
significant increase in the level of HRD1 occurred following these treatments (Fig. 2.4F, 
I). Importantly however, proteasome blockade increased the extent to which HRD1 co-
precipitated with endogenous Tomo-1 (Fig. 2.4B, J). These results indicate that 
perturbation of proteasome activity-dependent regulation not only affects Tomo-1 
protein level, but may also alter the extent of which Tomo-1 interacts with HRD1. 
 
HRD1 is Present in Neuronal Processes and Synapses 
As mammalian HRD1 is localized to the ER membrane we next examined by ICC 
if HRD1 is present within neuronal processes, such as dendrites, where it may possess 
the ability to ubiquitinate and spatially regulate postsynaptic Tomo-1. Indeed, the ER 
has been reported to extend from somatic areas, where it is heavily enriched, into 
dendritic shafts and spines of neurons (57). Furthermore, localized ER stress responses 
have been detected in dendrites of cultured mouse hippocampal neurons (58). As 
shown in Fig. 2.5A, ICC of HRD1 in neuronal cultures demonstrated extensive HRD1 
immunofluorescence within somata, as expected, but notably also within neuronal 
processes (Fig. 2.5A-B). A fluorescence intensity alignment profile of HRD1 and PSD95 
along straightened dendrites demonstrated localization within processes (Fig. 2.5B, 
bottom). However, the diffuse dendritic distribution of HRD1 suggested it was not 
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specifically located at sites of PSD95 fluorescent puncta (Fig. 2.5C, Pearson’s overlap 
coefficient; r=0.437, r2=0.191, Manders’ correlation coefficients; M1=0.724 (fraction of 
PSD95 overlapping HRD1), M2=0.517 (fraction of HRD1 overlapping PSD95)). 
The finding of an ER-localized E3 ligase within dendrites of primary hippocampal 
neurons suggests that HRD1 regulation of Tomo-1 may occur beyond the somatic 
compartment. As such, we next investigated if interaction between endogenous Tomo-1 
and HRD1 proteins occur in neurons, including processes, using a proximity-ligation 
assay (PLA) in fixed cultures. Interestingly, PLA fluorescent puncta indicated that Tomo-
1 and HRD1 interact within the somata and non-somatic regions (Fig. 2.5D, and inset). 
Specificity of this PLA interaction was demonstrated by the absence of a PLA signal 
when an interaction between Tomo-1 and the cytosolic exocytic regulatory protein 
Munc18 was tested. Furthermore, fluorescent puncta were not apparent in antibody 
omission control PLA reactions (data not shown). 
 
Tomo-1 Protein is Ubiquitinated Prior to Proteasomal Degradation 
To determine if Tomo-1 is subject to HRD1-mediated ubiquitination within 
neurons, we next infected neuronal cultures with an N-terminal tagged YFP-Tomo-1 
fusion protein, which efficiently precipitated with an anti-GFP nanobody (Fig. 2.6A). 
Importantly, IP samples from the YFP-Tomo-1 expressing neurons demonstrated 
ubiquitinated YFP-Tomo-1 conjugates (Fig. 2.6B). Conjugated-ubiquitin 
immunoreactivity was not apparent in IP samples of the Tomo-1 knockdown condition, 
in which cytosolic GFP was co-expressed. Furthermore, with GFP expression (Fig. 
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2.6C, top) no ubiquitin immunoreactivity was observed at 26kD, the molecular mass of 
GFP-family proteins, following GFP IP (Fig. 2.6C, bottom). This finding indicated that 
Tomo-1, and not the YFP (a GFP point mutant) fluoroprotein, was ubiquitinated. 
We next examined if ubiquitination of the exogenously expressed YFP-Tomo-1 
was altered by pharmacological proteasome blockade. As shown in Fig. 2.6D-F, the 
expression level of YFP-Tomo-1 was increased by approximately 1.5-fold vs. DMSO 
vehicle control after a 4-hour treatment with either MG or Lac. To mitigate 
deubiquitination in these experiments the broad-spectrum deubiquitinating enzyme 
(DUB) inhibitor PR-619 was co-applied with proteasome inhibitors. Fig. 2.6E, G shows 
that the increase in Tomo-1 level following proteasome blockade was accompanied by a 
significant increase in Tomo-1 ubiquitination, and, notably, the co-IP of HRD1 with YFP-
Tomo-1 also increased upon MG treatment. Importantly, the fraction of Tomo-1 that was 
ubiquitinated following proteasome blockade significantly increased relative to total 
Tomo-1 IP level. 
 
HRD1 Ubiquitinates Tomo-1 to Regulate its Level 
To determine if HRD1 is capable of directly ubiquitinating Tomo-1, we utilized an 
in vitro ubiquitination assay. For this assay, we expressed and affinity-purified Tomo-1 
protein from HEK293T cells, and used commercially available purified HRD1 and its 
various upstream cofactors (ubiquitin, UBE1, UBE2D2, and ATP). As shown in Fig. 
2.6H, Tomo-1 is ubiquitinated in a concentration-dependent fashion by HRD1. 
Moreover, significant ubiquitination above background did not occur in control 
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conditions lacking HRD1, Tomo-1, or ATP, or when testing the empty vector control 
expressed and purified in the same manner as Tomo-1. Replacement of either the 
upstream E2 ubiquitin-conjugating enzyme (with UBE2G2), or the HRD1 itself (by 
another E3 enzyme of the same RING-type class: CHIP/STUB1) failed to induce Tomo-
1 ubiquitination (data not shown). 
 
HRD1 Degrades Tomo-1 to Increase Dendritic Spine Density 
We next investigated if HRD1 ubiquitination and proteasomal targeting of Tomo-1 
may modify the density of dendritic spines. To address this question, we tested shRNA 
constructs for HRD1 KD, and examined their effect on endogenous Tomo-1 protein 
level in hippocampal neuronal cultures. Two lentivirus-driven shRNAs targeting non-
overlapping regions of HRD1 mRNA were tested. The shHRD1 constructs resulted in 
significant (39% and 47%) decreases in HRD1 protein level relative to a scrambled 
shRNA control, as determined by WB analysis of whole cell lysate samples (Fig. 2.7A). 
The incomplete KD of HRD1 within these neuronal lysates was likely the result of an 
only 56% transduction efficiency in cultured neurons (Fig. 2.7B). This suggests that the 
level of HRD1 within infected neurons may be lower than 50% of control. Viral infection 
was highly specific to neurons, as evidenced by neuronal-specific nuclei labeling with 
anti-NeuN. Our incomplete knockdown of HRD1 is of similar extent to previously 
reported RNAi-based knockdown of HRD1 in differentiated neurons (59). However, 
utilizing ICC fluorescence imaging to assess HRD1 KD efficiency, we observed that 
HRD1 fluorescence intensity levels in cells infected with a 50:50 mixture of both HRD1 
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shRNAs decrease approximately 72.2% as compared with SCR controls (Fig. 2.7C-D). 
Notably, the decrease found via WB analysis of HRD1 protein level following 52.5% 
knockdown resulted in a significant increase in Tomo-1 protein level by an average of 
140.6% of control (Fig. 2.7E-F). 
We next investigated the effects of HRD1 KD on dendritic spines, to determine if 
the effects of Tomo-1 on spine density are dependent upon regulation by HRD1. We 
performed confocal imaging and 3D reconstruction and analysis of dendritic spines as in 
Fig. 2.2. First, neuronal cultures were transfected with a soluble mCH fluorophore and 
co-transfected with either; shRNAs targeting HRD1 (HRD1 KD), or the scrambled 
shRNA vector. Each shRNA construct co-expresses a soluble GFP reporter 
fluorophore. Representative images for each condition are shown in Fig 2.8A. HRD1 KD 
was found to significantly increase average spine density, from 3.9 to 5.8 spines per ten 
micrometers, relative to the SCR control (Fig. 2.8B). This effect parallels that observed 
following Tomo-1 overexpression, suggesting that HRD1 may tune spine density via 
Tomo-1 ubiquitination and targeting for degradation. Effects of HRD1 KD exhibited a 
statistically significant on average spine length, but no effect was found on head 
diameter or volume (Fig. 2.8C-E). Cumulative spine frequency in the HRD1 KD was 
similar to the change observed for Tomo-1 overexpression (significant increase vs. 
respective controls) (Fig. 2.8F). We next tested if the alteration in spine density or 
cumulative spine frequency following HRD1 KD is related to specific actions of HRD1 on 
Tomo-1. This was assessed by simultaneous shRNA-mediated knockdown of Tomo-1 
and HRD1. Importantly, the effect of HRD1 KD to increase average spine density was 
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nearly completely blocked in the double KD condition (2KD, Fig. 2.8B, F). The 2KD 
condition also exhibited a significant increase in averaged spine head diameter, with an 
accompanying trend on spine head volume but not spine length (Fig. 2.8C-E). These 
data suggest that the actions of HRD1 on spine density occur directly on or within the 
Tomo-1 signaling pathway, which itself alters spine density. 
 
2.4 Discussion 
In the present study, we identify Tomo-1, a soluble R-SNARE motif-containing 
protein, as a novel positive regulator of the density of dendritic spines in cultured 
hippocampal neurons. Tomo-1 overexpression specifically increased dendritic spine 
density without influencing average spine length, maximum head diameter, or head 
volume. Conversely, Tomo-1 knockdown decreased dendritic spine density. Notably, we 
have also determined that Tomo-1 is an interacting partner of and a specific target 
substrate for ubiquitination by the E3 ligase HRD1, which subsequently promotes 
Tomo-1 degradation by the 26S proteasome. Ablation of HRD1 activity via targeted 
knockdown increased global Tomo-1 protein levels in cultured neurons. Furthermore, 
HRD1 knockdown increased dendritic spine density. This effect was blocked following 
simultaneous knockdown of HRD1 and Tomo-1, strongly suggesting a signaling 
pathway involving both proteins in determining spine density. Thus, our data show that 
HRD1-mediated regulation of Tomo-1 is a newly identified component in neuronal 
regulation of spine density by the UPS and, therefore, potentially on synaptic dynamics 
of hippocampal neurons. 
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Neurons are highly polarized cells, with complex regulatory mechanisms that 
control cell excitability, synaptic plasticity, and information transfer within the brain. 
Tomo-1 has conserved orthologs (60) across a diversity of organisms and systems, 
demonstrating their important function in membrane trafficking and intercellular 
signaling. In addition, Tomo-1 exhibits a low level of genic intolerance relative to that 
expected by neutral variation found in genes (RVIS -0.4 (27%) (61), suggesting that 
genetic variants of Tomo-1 may confer an increased risk of disease. Functionally, 
Tomo-1 has inhibitory actions on secretion within the brain (17), superior cervical 
ganglion neurons (36), bovine adrenal chromaffin cells (62), pancreatic ß-cells (25) and 
in PC12 (40, 63) and CHO (64) cell lines. The most commonly reported mechanism of 
Tomo-1 action has been its role in inhibiting the priming and concomitant fusion of the 
readily-releasable pool (RRP) of vesicles in neurons (19, 30, 65) and neuroendocrine 
cells (66). In addition to Tomo-1 actions on the RRP, Tomo-1 has recently been shown 
to control the proportional reallocation of neurotransmitter-containing vesicles between 
functionally identified presynaptic vesicle pools (30). 
The current study identifies a completely novel postsynaptic effect of Tomo-1 – 
the regulation of dendritic spine density in cultured hippocampal neurons. Interestingly, 
this action of Tomo-1 occurs independently of its C-terminal R-SNARE domain. The 
effects of Tomo-1 on dendritic spines may be analogous to known membrane trafficking 
and cytoskeletal regulation roles mediated by Tomo-1 orthologs. For example, two 
yeast Tomo-1 proteins, Sro7p/77p, together with Sec4 and Myo2 (18, 67-69), modulate 
	 68	
exocytosis by associating with cytoskeletal components and regulating SNARE function 
on the plasma membrane (31, 37). 
The key importance of Tomo-1 in orchestrating vesicle priming and exocytotic 
secretion of chemical messengers raises an imperative need to identify and 
characterize the signaling pathways which control it. However, identification of 
transcriptional, translational, and degradative mechanisms mediating the expression 
level of Tomo-1 and, potentially, the dynamic range of its activity in neurons, is lacking. 
The present study has uncovered a novel form of Tomo-1 protein regulation in central 
neurons via the ubiquitin-proteasome system. We have identified HRD1, an ER-resident 
RING-type E3 ubiquitin ligase, as a novel upstream regulator which specifically targets 
Tomo-1 for degradation. Indeed, PLA imaging data indicated that while endogenous 
Tomo-1 and HRD1 are abundant in the cell soma, they also generally appear to be 
overlapping within neuronal dendrites. Further, HRD1 was co-IPd with Tomo-1 from 
neuronal lysate, and in vitro reactions using purified HRD1 and Tomo-1 proteins 
demonstrated concentration-dependent Tomo-1 ubiquitination by HRD1. The potential 
for similar actions occurring in vivo is supported by our results demonstrating that 
pharmacological proteasome blockade, via bath application of MG132 or Lactacystin, 
increased neuronal Tomo-1 protein level. Moreover, this action occurred on a shorter 
timescale than the half-life of most synaptic proteins (70), suggesting that ubiquitination 
may be used to selectively target Tomo-1 for rapid proteasomal degradation. However, 
future consideration is warranted for the concurrent examination of Tomo-1 biosynthetic 
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activity, as production rates may be linked to reduced UPS-mediated degradation or 
actions of proteasome blockers. 
A proteomics screen of pull-down samples of Tomo-2 from the insulin-secreting 
INS1 ß-cell line also identified HRD1 as one of the highest confidence Tomo-2 
interacting partners, in addition to HRD1 adaptor proteins (43). It is currently unknown at 
which lysine residues Tomo-1 is ubiquitinated by HRD1, nor to what extent 
ubiquitination alters the half-life of Tomo-1. Nonetheless, HRD1’s well-established 
function in ubiquitinating target substrates for proteasomal degradation during ER-
associated degradation (ERAD) can now be expanded to include actions within 
dendrites and on synaptic proteins. In addition, as Tomo-1 and HRD1 colocalize to 
dendrites where they likely interact, the potential exists for localized regulation of Tomo-
1 protein level within, or near, postsynaptic sites. A rapid, potentially local, degradation 
of Tomo-1 may occur in a similar fashion to dephosphorylation-induced, UPS-mediated 
degradation of fragile X mental retardation protein (FMRP) in the dendrites and 
synapses of cultured rat neurons (71). 
Specific E3 ubiquitin ligases are known to influence synaptic physiology and 
plasticity in both non-proteolytic (72) and proteolytic-dependent manners (73). Some of 
these have been shown to be dependent upon postsynaptic activity (11, 74, 75). Spine 
morphogenesis and number (76), as well as spine maintenance (77), including specific 
AMPA receptor subunit levels and membrane integration (78), are tightly controlled by 
the UPS. Within the microenvironment of the synapse, targeted protein degradation 
involving many specific E3 ubiquitin ligases, confers substrate specificity in 
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ubiquitination. Indeed, numerous neuronal E3s have been identified that functionally 
regulate specific levels of postsynaptic proteins. These include γ-actin (79), GKAP, and 
Shank (80), which are regulated by TRIM3, PSD95 by Mdm2 (13) upon facilitation by 
CDK5 (81), AMPARs by RNF167 (82) and Nedd4-2 (94), and the postsynaptic 
cytoskeletal protein and immediate early gene Arc by both UBE3A (83) and 
RNF216/TRIAD3 (84). Targeted ubiquitination of presynaptic proteins is also prominent. 
For example, the active zone (AZ) protein RIM1, which scaffolds the multi-protein 
modules which regulate priming and release of NT-containing vesicles, is acted upon by 
the E3 ligase SCRAPPER and results in rapid alteration in presynaptic release (85). 
Furthermore, the AZ proteins Bassoon and Piccolo, which are subject to regulation by 
the E3 ligase Siah1, were shown to be crucial in the ubiquitination and maintenance of 
numerous presynaptic proteins (8). 
Prior reports have identified HRD1 as important in regulating neuronal cell 
biology. For example, upregulation of HRD1 following ER stress in differentiated 
neurons decreases neurite outgrowth and dendritic arborization (59). Furthermore, 
HRD1 has been shown to promote the degradation of other components of the synaptic 
proteome, including the Parkin-associated endothelin receptor-like receptor, PaelR (55) 
and expanded polyglutamine variants of Huntingtin (86). Our results indicate that HRD1, 
which is well known to act on membrane delimited proteins, also regulates the cytosolic 
protein Tomo-1. While HRD1 targeting of soluble proteins has been rarely reported, it 
has been shown to facilitate proteasomal degradation and aggresome formation of 
Optineurin (87), a cytosolic protein involved in the maintenance of the Golgi complex, 
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membrane trafficking, and exocytosis. Interestingly, Optineurin, like the Tomo-1 
orthologs Sro7p/77p, is reported to interact with myosin and Rab family proteins (31, 38, 
88). 
E3 ligase-mediated ubiquitination of substrate proteins is often sensitive to the 
state of the target protein’s PTMs. Tomo-1 is regulated via multiple modifications, 
including phosphorylation at specific amino acid sites by PKA (36), Akt/PKB (64), and 
CDK5 (30) kinases, in addition to SUMOylation (40), which is mediated by the E3 PIAS 
(41). Furthermore, there is a growing body of evidence indicating facilitated co-
regulation of protein substrates by phosphorylation, ubiquitination, and other PTMs. For 
example, CDK5, a kinase recently reported to phosphorylate Tomo-1 and exert a 
functional impact on the RRP, is downregulated following the S-nitrosylation of its 
upstream activator p35. This causes p35 ubiquitination by the E3 PJA2 and degradation 
(89). While the physiological signal driving HRD1-mediated ubiquitination of Tomo-1 is 
unknown, it may result from up- or down-regulated PTM of Tomo-1, or indirectly 
following the PTM of kinases and other upstream Tomo-1 regulators. Such integrative 
mechanisms may serve to balance the rate and targets of degradation and also provide 
the possibility for diversity in subcellular localization and activity-dependence. 
Ubiquitination and proteasomal degradation of synaptic proteins does not 
necessarily indicate an impact on plasticity. It is currently unknown if the relationship 
between Tomo-1 and HRD1 is regulated following neuronal activity, for example, in a 
homeostatic fashion. TOM-1, a Tomo-1 ortholog in C. elegans was, however, reported 
to increase presynaptically in response to neurexin/neuroligin-mediated retrograde 
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downregulation of presynaptic NT release (39). The molecular mechanism driving the 
change in TOM-1 protein level remains uncharacterized. Furthermore, we have 
previously shown that Tomo-1 contributes to CNQX-induced synaptic scaling in 
hippocampal neurons (30), a form of homeostatic plasticity occurring following synaptic 
inactivation via AMPAR blockade. Future investigations are required to address the 
physiological parameters regulating HRD1-mediated Tomo-1 ubiquitination and the 
resulting functional consequences. 
 
2.5 Materials and Methods 
Animals 
All animal handling procedures are approved by and in full compliance with the 
regulations of the University Committee on Use and Care of Animals of the University of 
Michigan, in addition to the National Institutes of Health guidelines. 
 
Antibodies 
Affinity-purified Rb anti-Tomosyn-1 polyclonal antibody (catalog no. 183103), and 
affinity-purified Rb anti-Tomosyn-2 polyclonal antibody (catalog no. 183203), and the 
Ms anti-PSD95 monoclonal antibody (catalog no. 124011) were from Synaptic Systems 
(Göttingen, Germany). The Ms anti-b-actin monoclonal antibody (clone AC74, catalog 
no. A2228) was from Sigma-Aldrich (St. Louis, MO). The Rb anti-HRD1 polyclonal 
antibody (catalog no. 13473-1-AP) was from ProteinTech (Chicago, IL). The Ms anti-
conjugated-ubiquitin monoclonal antibody (clone FK2, catalog no. BML-PW8810) was 
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from Enzo Life Sciences (Farmingdale, NY). The Ms anti-GFP antibody (clone C163, 
catalog no. 33-2600) was from ThermoFisher (Waltham, MA). For western blots, IRDye 
800CW-conjugated goat anti-mouse IgG H+L (catalog no. 926-68021) and IRDye 
680LT-conjugated goat anti-rabbit IgG H+L (catalog no. 926-32210) fluorescent 
secondary antibodies were from Li-Cor Biosciences (Lincoln, NE). For light microscopy 
immunocytochemistry Alexa Fluor 488-, 594-, and 647-conjugated species-specific anti-
IgG secondary antibodies raised in goat (catalog nos. A11073, A11012, and A21236 
respectively) were from Invitrogen (Waltham, MA). Affinity-purified Ms anti-NeuN 
(neuronal nuclei) monoclonal antibody (Clone A60, catalog. no. MAB377) was from 
Millipore (Billerica, MA). 
 
Cell Culture and Transfections 
All results were obtained from dissociated rat hippocampal neuronal cultures (17-
28 DIV), unless otherwise noted. Hippocampal neuronal cultures were prepared as 
previously described, with minor adjustments (90). Briefly, hippocampal neurons from 
embryonic day 19-20 Sprague-Dawley rats of either sex (Charles River) were plated at 
400-450 cells/mm2 on either 18mm diameter, #1.5 thickness coverglass (Neuvitro, 
catalog no. GG-18) or on 14mm microwell glass- bottom 35mm culture dishes (MatTek, 
catalog no. P35G-0.170-14-C) and maintained in an incubator containing 95%/5% 
O2/CO2 and 100% humidity at 37°C in NBActiv4 medium (catalog no. Nb4, BrainBits, 
Springfield, IL) for up to 4 weeks in vitro prior to experimentation. Half of the neuronal 
culture medium was replaced every 3-4 days until experimentation. 
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 Hippocampal cultures were co-transfected at 13-21 DIV for spine imaging at 17-
25 DIV. Transfection was achieved using 200μL of NBActiv4, including 1μL 
Lipofectamine 2000 (Invitrogen, catalog no. 11668019) per dish and pCAG-mCherry 
(0.4μg/dish), in addition to one of the following constructs (1μg/dish): GFP-shTomo-1, 
GFP-shHRD1, GFP-shSCR, GFP-Tomo-1, GFP-Tomo-1 lacking the C-terminus. 
Transfection solutions were allowed to stand for 30 min. before being dripped onto the 
cell cultures. Cultures were incubated for 1 hour with the Lipofectamine/DNA mix, after 
which media was exchanged with fresh NBActiv4 media. Pyramidal neurons were then 
imaged 3-5 days post-transfection. 
HEK293T cells (catalog no. CRL-3216, ATCC, Manassas, VA, ≤15 passages) 
were seeded in plastic T-75 tissue culture flasks at <75% confluence in an incubator 
containing 95%/5% O2/CO2 and 100% humidity at 37°C in DMEM (Gibco catalog no. 
11960) containing: 10% FBS (Gibco catalog no. 10437-028), 1% glutamax 
(ThermoFisher, catalog no. 35050061), 1% penicillin-streptomycin (Sigma, catalog no. 
P4333), and 1% non-essential amino acids (Gibco, catalog no. 11140-050). 
 
Cloning of Full-length Rat m-Tomo-1 Constructs into the Gateway Expression Vector 
The coding sequence of rat m-Tomosyn-1 (NCB accession # NP_110470.1) was 
cloned into the NativePure Gateway destination vector pcDNA3.2/capTEV-CT/V5-DEST 
(Invitrogen, catalog no. BN3002) for expression in HEK293T cells and native affinity 
purification for use in the in vitro ubiquitination reactions. 
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Drugs 
The following chemicals were used for this study, as noted: DMSO (Life 
Technologies, catalog no. D12345), MG132 (Cayman Chemicals, catalog no. 
10012628), Lactacystin (Tocris, catalog no. 2267), PR-619 (Tocris, catalog no. 4482). 
Where noted, protease inhibitor cocktail minus EDTA (Roche, catalog no. 11580800) 
was added to lysis and/or IP buffers. 
 
Image Acquisition, Analysis, and Quantification 
Live cell imaging of neuronal spines was performed on a Nikon Eclipse Ti 
inverted microscope operating a Nikon A1 laser-scanning confocal system. Specimens 
were housed under incubation conditions throughout imaging in a gas-, temperature-, 
and humidity-controlled imaging chamber (Tokai Hit). Laser illumination was provided at 
488nm (air-cooled, argon ion laser at 40 mW, Spectra-Physics) and 543nm (HeNe laser 
at 5 mW, Melles Griot). Fluorescence images were acquired with the NIS Elements AR 
imaging suite (Nikon, version 4.51.00) with pinhole size set to 57.5µm (2 A.U.) using a 
60X oil-immersion objective (Plan Apo 60X Oil DIC N2) and 3X digital zoom. Images 
were captured at 1024x1024 pixels, with a 0.5 frames/second scan speed and 0.338µm 
Z-step size. Identical settings for laser intensity and background offset were maintained 
between all experimental conditions. An entire dendrite emanating from one somatic 
branch point per neuron was fully imaged and auto-compiled into a Z-stack. The Z-
stacks were then re-constructed in 3D and analyzed offline using Imaris 7 software 
(Bitplane, version 7.7.2). Automated detection and analysis of spines was performed on 
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single dendrites from point of initiation at the soma through 150μm of dendrite shaft 
length. 
 ICC imaging was performed on an Olympus BX61WI upright laser-scanning 
confocal microscope using a 20X, 0.75NA air (Olympus America, catalog no. 
UAPO340) or 60X, 1.42NA oil-immersion objective (Olympus America, catalog no. 
PLAPON-60X) at 1024x1024 pixels image size and 10µs pixel dwell time. Identical 
settings for gain, laser intensity, background offset, and pinhole size were maintained 
between all experimental conditions. Fluorescence images were then analyzed offline 
with the FIJI imaging suite, including the JACoP plugin (91). 
PLA experiments were imaged on an Olympus IX-81 inverted spinning-disc 
confocal microscope using an ApoN 60X, 1.49 NA oil-immersion objective (Olympus 
America, catalog no. APON 60XOTIRF) in wide-field (disc-out) configuration. 
Illumination was provided by a 300W xenon arc lamp (Sutter Instrument, LB-LS/30) 
coupled to an electronically-shuttered liquid light guide for controlled transmission of 
light to the microscope optics. Images were captured with an ImagEM EM-CCD camera 
(catalog no. C9100-13, Hamamatsu City, Shizuoka, Japan) with 16μm pixel-size using 
Metamorph image acquisition software (software version no. 7.7.1.0, Molecular 
Devices, Sunnyvale, CA). The following optical filter-sets were used for DAPI, mCherry 
and GFP fluorophores, respectively: excitation 405/25; 472/30; 416/25, and emission 
450/30; 520/35; 464/23. 
 
Immunocytochemistry and Proximity Ligation Assay 
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ICC was performed on cultured hippocampal neurons adhered to the center wells 
of glass-bottomed 35mm dishes pre-coated with poly-D-lysine (catalog no. P35GC-1.5-
14-C, MatTek, Ashland MA) as listed above. Cells were fixed and stained according to 
published protocol (92). All antibody dilutions and rinses were in PBS + 3% BSA. 
Primary antibodies were added at indicated dilutions for one hour, followed by rinses 
(5x, 5 min. each) and addition of secondary antibodies for 45 minutes, followed by 
rinses as above, and stored in Vectashield with DAPI (catalog no. H-1200, Vector Labs, 
Burlingame, CA) at 4°C prior to imaging. PLA reactions were performed in the exact 
fashion as ICC procedures through primary antibody incubation. Next, anti-rabbit PLA+ 
(catalog no. DUO92002) and anti-mouse PLA- (catalog no. DUO92004) probes (Sigma-
Aldrich) were added for 45 min. at 37°C, followed by rinses (3x, 5 min. each, in PBS 
containing 0.2% BSA, 0.1% Triton X-100). Next, ligation and amplification solutions (kit 
catalog no. DUO92007) were sequentially added for 30 and 100 min., respectively, with 
rinses as above between and prior to imaging. 
 
Immunoprecipitation of Endogenous Tomosyn-1 and HRD1 from Hippocampal Neuronal 
Culture 
Immunoprecipitation of endogenous protein from cultured hippocampal neurons 
was performed using either the Tomo-1-specific or HRD1 antibodies noted above by 
pre-binding 2μg antibody to 50μL protein A magnetic dynabead slurry (Pierce, catalog 
no. 88845) per 35mm dish in 100mM Na-phosphate buffer (pH 8.0) containing (mM): 75 
Na2HPO4 and 25 NaH2PO4. Cultures were lysed and collected in non-denaturing lysis 
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buffer (pH 7.5) containing (mM): 50 NaCl, 25 Tris, 2 MgCl2, 1 CaCl2, 0.5% NP-40, and 
2x recommended concentration of complete EDTA-free protease inhibitor cocktail. 
Samples were then equalized for total protein concentration (1-3μg/μL) and sample 
volume (100-300μL) prior to incubation with the conjugated beads for one hour at 4°C. 
The samples were then rinsed in lysis buffer and boiled in 1x SDS sample buffer for five 
minutes before being loaded for PAGE and western blotting. 
 
In Vitro Ubiquitination Assay 
The Gateway rat m-Tomosyn-1 construct noted above was used to express 
Tomo-1 in HEK293T to encourage proper post-translational modification and 3-
dimensional protein structure prior to experimental procedures. Cells were seeded at 
50% confluence from liquid nitrogen stocks in 10cm cell culture dishes for ≈ 16 hours 
and serum-starved in 10mL Opti-MEM (Gibco catalog no. 31985) for one hour prior to 
transfection. Transfection occurred using 25μg plasmid DNA and 25μL Lipofectamine 
2000 (Invitrogen, catalog no. 1166809) in 10mL Opti-MEM, per dish, for five hours 
under standard incubator conditions before standard HEK cell medium replacement. 48-
72 hours following transfection the cells were lysed under non-denaturing conditions in 
lysis buffer containing (mM): 100 Tris, 100 KCl, 0.2 EDTA, 1.5 MgCl2, 0.01 pepstatin-A 
(Sigma, catalog no. P5318) and protease inhibitor cocktail minus EDTA (Roche) at 2x 
recommended concentration. Lysates were then subjected to 3 freeze-thaw cycles 
using liquid nitrogen and centrifuged at 3,000xG for 10 minutes for de-nucleation. NP-40 
was added to the lysate supernatants to a final concentration of 1% v/v. Lysates were 
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then incubated with streptavidin-agarose beads (Invitrogen, catalog no. S951) for three 
hours at 4°C to purify the biotinylated epitope-tagged m-Tomo-1 fusion construct. Final 
purity and protein concentration were quantified using a serial dilution vs. BSA standard 
on a coomassie-stained SDS-PAGE gel. 
For use in ubiquitin reactions, 2μg purified Tomosyn-1 bound to the streptavidin-
agarose beads was suspended in assay buffer containing the following (mM): 100 Tris, 
10 MgCl2, and 0.2 DTT (Invitrogen, catalog no. 15508-013) and subjected to the 
following reaction conditions at 37°C for 45 minutes with mixing (E3Lite Ubiquitin Ligase 
Kit, catalog no. UC101, LifeSensors, Malvern, PA): 20μg/mL wild-type human ubiquitin 
(catalog no. SI201), 10nM UBE1 (catalog no. UB101), 100nM UBE2D2 (catalog no. 
UB207H), 16-250nM HRD1 (catalog no. UB307), 200μM ATP (catalog no. A50-09-200, 
SignalChem, Richmond, BC, Canada). Negative control experiments were run exactly 
as described above, with substitution of the E2 UBE2D2 with UBE2G2 (catalog no. 
UB227) or the E3 HRD1 with CHIP/STUB1 (catalog no. UB309). 
 
RNA Interference and Lentiviral Construct Generation for Targeting HRD1 and Tomo-1 
Lentiviral vectors encoding a short hairpin RNAi (shRNA) for targeted knockdown 
of rat HRD1 were created in the pGFP-C-shLenti and pRFP-CB-shLenti expression 
vectors (Origene, Rockville, MD, catalog nos. TL704173 and TR30032) which 
independently encode (via U6 promoter) the following shRNA sequences, respectively: 
TGGTTGGCTGAAGACCGTGTGGACTTTAT, 
TTGTCAGCCACGCTTATCACAGCATCCTG. Non-targeted scrambled shRNA 
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sequences (shSCR): CAGGAACGCATAGACGCATGA, in the same lentiviral vectors 
were used for control experiments. Targeted knockdown of all Tomo-1 isoforms was 
accomplished using the same vector with the following custom shRNA sequence 
inserted: ACTGCTTCAGCCAGTGATTGTGTCTCCAA. 
All shRNA constructs were packaged and produced at the University of Michigan 
Vector Core (Ann Arbor, MI). Briefly, HEK293T cells were Lipofectamine-transfected 
with vectors encoding REV, MDL, pvSVG, and each lentiviral plasmid-containing 
expression construct. At 42 hours post-transfection, the virion-containing medium was 
collected, filtered through a 0.45μm filter to remove cell debris, and ultra-centrifuged at 
42,152xG at 4°C for 2H. The supernatant was then discarded and the viral pellet gently 
resuspended in 10mL NBActiv4 neuronal culture medium (to ≈ 1x107 MOI/mL). 500μL 
aliquots were quickly frozen and stored at -80°C. Neuronal cultures were treated with a 
1:5 (HRD1 knockdown) or 1:10 (Tomo-1 knockdown) dilution of virus at 10-18 DIV and 
allowed to express for 4-7 days before experimentation. 
 
Western blotting 
SDS-PAGE gels were wet-transferred onto nitrocellulose membranes at 10V for 
1.2 hours and blocked in non-mammalian Odyssey blocking buffer (Li-Cor Biosciences, 
Lincoln, NE, catalog no. 927-40000). Blocking, primary antibody, and secondary 
antibody incubations were all performed for 1 hour at room temperature and were rinsed 
3x for 5 minutes each in PBS + 0.1% Tween-20 (PBS-T) between incubations. All 
primary antibodies were used at a 1:1,000 dilution in PBS-T for western blotting, except 
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for the following: anti-b-actin (AC74) 1:8,000, anti-GFP (C163) 1:8,000, and anti-
ubiquitin (FK2) 1:250. All secondary antibodies were used at a 1:15,000 dilution in PBS-
T. Western blot images were collected with an Odyssey CLx Infrared Imaging System 
(Li-Cor model no. 9120) at 84µm resolution in high quality mode and within the linear 
range of exposure. Fluorescence density was quantified with the open-source ImageJ 
software including the FIJI imaging suite (93) and the gel analyzer plugin. 
 
YFP-Tomo-1 Protein Expression and Purification 
Mouse m-Tomosyn-1 (NCB accession # NP_001074813.2) cloned into the 
pLenti-hSyn-eYFP backbone (22) was provided by Dr. Uri Ashery (Tel Aviv University) 
and used for efficient transduction and expression in cultured hippocampal neurons, as 
well as for immunoprecipitation following in vivo ubiquitination experiments. 
Immunoprecipitation of YFP-Tomosyn proteins was performed using GFP-Trap 
magnetic beads (catalog no. gtma20, ChromoTek, Planegg, Germany). Cells were 
lysed in buffer containing: 150mM NaCl, 50mM Tris, 1% NP-40, 10μM PR-619, and 2x 
recommended concentration of protease inhibitor cocktail. Lysates were centrifuged at 
10,000xG and supernatants assayed using the Bradford method for total protein 
quantification. Total protein and volume equalizations were performed on all samples 
prior to incubation with the anti-GFP beads for 90 minutes at 4°C to purify the YFP-
Tomosyn fusion construct. The samples were then rinsed in lysis buffer and boiled in 
1.5X LDS sample buffer + reducing agent (Invitrogen, catalog nos. B0007, B0009) for 
10 minutes before being loaded for PAGE and western blotting. 
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Statistical Analyses 
All statistical analyses were performed with Prism 6 (version 6.0f, Graphpad 
Software, La Jolla, CA). Where indicated two-tailed t-tests or analysis of variance 
(ANOVA) were used for comparisons of population means. Post-hoc t-tests were used 
for multiple comparisons between specific groups. Cumulative frequency distributions 
were compared using a Kolmogorov-Smirnov test. Sample means throughout are 
presented ± SEM, with significance thresholds set to # p < 0.1; * p < 0.05; ** p < 0.01 for 
all tests. 
 
Use of Biological Replicates 
Each experiment performed in the current study used unique and independent 
samples (n = culture dishes for protein level biochemistry; reactions for in vitro 
ubiquitination assays; single dendrites of individual neurons for spine analysis; neurons 
for ICC imaging) including paired controls where noted. Significant results were 
determined from at least three independent neuronal preparations. 
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Figure 2.1: Knockdown, overexpression, and rescue of Tomo-1 protein in 
hippocampal neurons. 
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Figure 2.1: Knockdown, overexpression, and rescue of Tomo-1 protein in 
hippocampal neurons. 
 
A, Representative LSCM fluorescence micrographs of shRNA expression reporter 
(tRFP, red), Tomo-1 expression (anti-Tomo-1, green), and merged overlays in neurons 
following expression of the scrambled shRNA control (SCR) or an shRNA targeting 
Tomo-1 for KD. Scale = 10μm. B, Fluorescence micrographs of a neuron expressing 
Tomo-1 shRNA (red) + shRNA-resistant mCH-Tomo-1 (green, Rescue). C, Comparison 
of Tomo-1 expression by WB (20μg/lane) following lentiviral-infection with; scrambled 
shRNA vector control (SCR), shRNA targeting Tomo-1 + GFP (KD), GFP-Tomo-1 fusion 
protein (Tomo-1), or an shRNA-resistant mCH-Tomo-1 (Rescue). D, Lentiviral infection 
with an shRNA targeting Tomo-1 for knockdown (red) decreases Tomo-1 intensity to 
49.1 ± 2.3% (via WB, n = 4) and 47.4 ± 3.1% (via ICC, n =8) of scrambled shRNA 
control vector (grey). All data presented as population mean ± SEM, with n# defined as 
individual neurons or independent culture dishes. Statistical significance (**, p < 0.01), 
where indicated, was determined vs. SCR vector control using was determined using 
two-tailed t-tests. 
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Figure 2.2: Effect of Tomo-1 protein abundance on dendritic spine density. 
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Figure 2.2: Effect of Tomo-1 protein abundance on dendritic spine density. 
 
A, GFP-Tomo-1 expression within a fixed dendrite indicates Tomo-1 OE localizes to 
dendritic spines (white arrowheads), scale bar = 10μm. B, Representative fluorescence 
micrographs of dendrites in transfected neurons expressing cytosolic mCH (red) and 
one of the following; GFP control (GFP, n = 9), GFP-Tomo-1 (Tomo-1, n = 8), GFP-
Tomo-1 ∆CT, (n = 13), scrambled shRNA control (SCR, n = 7), Tomo-1 shRNA (KD, n = 
14), or Tomo-1 shRNA + shRNA-resistant mCH-Tomo-1 (Rescue, n = 7), scale bar = 
10µm. C-F, Averaged spine density (C), spine length (D), maximum spine head 
diameter (E), and spine head volume (F) for each indicated condition. G-H, Comparison 
of cumulative frequency distributions of spine density in neurons in each condition. All 
data presented as population mean ± SEM, with n# defined as individual dendrites or 
neurons from independent culture dishes. Statistical significance (#, p<0.1; *, p < 0.05; 
**, p < 0.01), where indicated, was determined vs. GFP or SCR vector controls using 
one-way ANOVAs with multiple comparisons of the mean or Kolmogorov-Smirnov tests 
of cumulative frequency distributions. 
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Figure 2.3: Tomo-1 localizes within postsynaptic compartments and is sensitive 
to shRNA-mediated knockdown. 
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Figure 2.3: Tomo-1 localizes within postsynaptic compartments and is sensitive 
to shRNA-mediated knockdown. 
 
A, ICC of Tomo-1 (green) in HEK293T cells following expression of mCH (red) with; (i) 
empty vector, (ii) Tomo-2, (iii) Tomo-1, or (iv) Tomo-1 (secondary antibody only), scale 
bar = 10μm. B, Anti-Tomo-1 WB of lysates from non-transfected HEK293T cells versus 
cells transfected with Tomo-1 or Tomo-2. C, Representative ICC image of hippocampal 
neuron displaying merged fluorescence of endogenous Tomo-1 (green), PSD95 (red), 
and nuclei (blue, DAPI), scale bar = 10μm. D, Representative intensity line scans of 
Tomo-1 (green) and PSD95 (red) fluorescence of an individual straightened dendrite 
indicate coincident immunofluorescence (lower plot). Merged Tomo-1+PSD95 
fluorescence (lower micrograph). E, Cytofluorogram of Tomo-1 and PSD95 intensities 
from the dashed box region in part D (Pearson’s overlap coefficient; r=0.885, r2=0.783, 
Manders’ correlation coefficients; M1=0.759; representing fraction of PSD95 
overlapping Tomo-1, M2=0.889; representing fraction of Tomo-1 overlapping PSD95). 
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Figure 2.4: Effect of proteasome blockade on neuronal Tomo-1 protein and its 
interaction with the E3 ligase HRD1. 
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Figure 2.4: Effect of proteasome blockade on neuronal Tomo-1 protein and its 
interaction with the E3 ligase HRD1. 
 
A, WBs of neuronal cultures treated with proteasome inhibitors MG132 (MG, 50μM, 4H) 
or Lactacystin (Lac, 10μM, 4H) vs. DMSO vehicle control on endogenous Tomo-1 
protein levels. B, WB of proteasome treatments, as in part A, on Tomo-1 IP and HRD1 
co-IP levels. C, IP of Tomo-1 co-IPs HRD1, however IgG control IP does not co-IP 
HRD1. Tomo-1 was immunodepleted from lysates (Input), with little immunoreactive 
Tomo-1 in post-IP supernatant (Super). D, The Tomo-1 antibody is selective for 
precipitating Tomo-1 protein from lysates as Tomo-1 IP (15 DIV, 20μg/sample), but not 
rabbit IgG control (Rb. IgG) or Tomo-2, showed Tomo-1 immunoreactivity. E, IP of 
VAMP2 does not result in co-IP of HRD1. F, Treatment of cultures with the proteasome 
inhibitors, as in part A, resulted in no significant change in endogenous HRD1 in lysate. 
Data are normalized against ß-actin protein levels (MG; n=7, Lac; n=7). G, 
Quantification of Tomo-1 inputs from part A (normalized to ß-actin protein levels, MG; 
n=28, Lac; n=21). H, Quantification of Tomo-1 IPs from part B. Averages are presented 
as percent change vs. vehicle-treated controls (dotted line, MG; n=7, Lac; n=7)). I-J, 
Quantification of HRD1 from lysate inputs (I) and HRD1 co-IP with Tomo-1 (J), (MG; 
n=6, Lac; n=7). All data presented as population mean ± SEM, with n# defined as 
independent neuronal culture dishes. Statistical significance (#, p < 0.1; *, p < 0.05; **, p 
< 0.01), where indicated, was determined using two-tailed t-tests. 
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Figure 2.5: The E3 ligase HRD1 is present throughout neuronal processes and 
interacts with Tomo-1. 
 
  
A.
HRD1 PSD95DAPI
B.
100 200 300 400
0.0
0.5
1.0
Distance (px)
R
el
. I
nt
. (
F/
F m
ax
)
C.
PSD95 Int. (A.U.)
HR
D1
 In
t. 
(A
.U
.)
103
105
104
103 105104
Tomo-1 + Munc18 Tomo-1 + HRD1 Inset
D.
	 93	
Figure 2.5: The E3 ligase HRD1 is present throughout neuronal processes and 
interacts with Tomo-1. 
 
A, Representative ICC image showing merged immunoreactive fluorescence of 
endogenous HRD1 (green), PSD95 (red), and nuclei (DAPI, blue) in cultured neurons, 
scale bar = 10μm. Note presence of HRD1 in dendrites. B, Representative fluorescence 
intensity line scans of HRD1 (green) and PSD95 (red) of an individual straightened 
dendrite indicate coincident immunofluorescence (lower plot). Merged Tomo-1+PSD95 
fluorescence is also shown (lower micrograph). C, Cytofluorogram analysis of 
fluorescence intensity relationship between HRD1 and PSD95 from dashed box region 
on dendrite highlighted in part B (Pearson’s overlap coefficient; r=0.437, r2=0.191, 
Manders’ correlation coefficients; M1=0.724; representing fraction of PSD95 
overlapping HRD1, M2=0.517; fraction of HRD1 overlapping PSD95), indicates a lack of 
specific colocalization. D, Representative Tomo-1 and HRD1 interaction assessed via 
proximity ligation analysis (PLA) demonstrates substantive numbers of fluorescent 
puncta in somatic regions and along neuronal processes (12 DIV), scale bar = 10μm. 
Inset expands outlined region. PLA testing for interaction between Tomo-1 and the 
synaptic protein Munc18 (top) resulted in low levels of fluorescent puncta similar to 
secondary antibody treatment alone (not shown).  
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Figure 2.6: Tomo-1 in hippocampal neurons is subject to in situ ubiquitination 
and is ubiquitinated in vitro by HRD1. 
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Figure 2.6: Tomo-1 in hippocampal neurons is subject to in situ ubiquitination 
and is ubiquitinated in vitro by HRD1. 
 
A-B, WB of YFP-Tomo-1 IPs from lentivirus-infected neurons were probed for 
immunoreactivity against Tomo-1 (A) and conjugated-ubiquitin (B). Neuronal infection 
with a lentivirus expressing shTomo-1 and free GFP demonstrated no anti-conjugated-
ubiquitin reactivity at 26 kD (B). C, WB of GFP (top) and conjugated ubiquitin (bottom) 
following GFP IP from infected neurons. D, WB for endogenous Tomo-1 and expressed 
YFP-Tomo-1 from lysates of neurons following treatment with the proteasome inhibitors 
MG (50μM, 4H) or Lac (10μM, 4H). E, WB of Tomo-1 IP probed for conjugated ubiquitin 
(top) and for HRD1 (bottom) following treatment with proteasome inhibitors + 10µM PR-
619 (PR). F, Averaged YFP-Tomo-1 and ß-actin levels from part D (MG n=18, Lac 
n=13). G, Averaged ubiquitinated Tomo-1 level and HRD1 co-IP levels from part E (MG, 
n=10; Lac, n=8). Above data (F-G) presented as population mean ± SEM, with n# 
defined as independent neuronal culture dishes. Averages are expressed as percent 
change relative to paired, vehicle-treated experimental controls (dotted line). Statistical 
significance (#, p < 0.1, *, p < 0.05, **, p < 0.01) was determined using two-tailed t-tests. 
H, Concentration-dependent in vitro ubiquitination of purified Tomo-1 by HRD1. Inset 
displays anti-ubiquitin WB of representative reaction product. Data are expressed 
relative to background and negative controls with significance (*, p < 0.05; **, p < 0.01, 
n=3) determined via multiple comparisons ANOVA. 
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Figure 2.7: Knockdown of HRD1 protein and functional relationship with Tomo-1. 
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Figure 2.7: Knockdown of HRD1 protein and functional relationship with Tomo-1. 
 
A, Histograms of shRNA-mediated decreases in HRD1 from virally-transduced cultures 
with two different shRNA KD sequences targeting HRD1 (mean ± SEM, multiple 
comparisons ANOVA, *, p < 0.05, **, p < 0.01, n=3). B, Representative images of 
shHRD1-infected neuronal cultures. Transduction efficiency was quantified by counting 
shHRD1-expressing neurons (GFP-positive, middle) versus the total number of neurons 
present (anti-NeuN, top). Transduction efficiency averaged 56%, with < 8% non-
neuronal infection (n=1,972 neurons, 20 FOVs, 4 dishes), scale bar = 50μm. C, 
Representative LSCM fluorescence micrographs of shRNA expression reporter (tRFP, 
red), HRD1 expression (anti-HRD1, green), and merged overlays in neurons following 
expression of the scrambled shRNA control (SCR) or an shRNA targeting HRD1 for KD, 
as in part B. Scale bar = 10μm. D, Histograms of shRNA-mediated decrease in HRD1 
level following ICC of cultures infected with a 1:1 ratio of both HRD1 shRNA KD vectors. 
Values (mean ± SEM, n=9) are normalized to anti-HRD1 ICC signal in scrambled 
shRNA (SCR) infected neurons. E, WB comparison of neuronal HRD1 expression 
between lentiviral-infected SCR and HRD1 shRNA KD. F, Histogram comparing HRD1 
and Tomo-1 expression levels in neuronal cultures treated with a mix of the HRD1 KD 
shRNAs (green) or SCR control (grey). All data presented as population mean ± SEM, 
with n# defined as individual neurons or independent culture dishes (HRD1 n=17, 
Tomo-1 n=14). Statistical significance (*, p < 0.05; **, p < 0.01), where indicated, was 
determined vs. SCR vector control using two-tailed or multiple t-tests. 
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Figure 2.8: Effect of HRD1 protein abundance on dendritic spine density. 
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Figure 2.8: Effect of HRD1 protein abundance on dendritic spine density. 
 
A, Representative LSCM fluorescence micrographs of dendrites emanating from 
cultured hippocampal neurons transfected with and expressing cytosolic mCH (red) and 
HRD1 shRNA (HRD1 KD), or Tomo-1 shRNA + HRD1 shRNA (2KD), scale bar = 10µm. 
B-E, Comparison of averaged spine density (B), spine length (C), spine head maximum 
diameter (D), and spine head volume (E) of individual neurons (14-28 DIV) for the 
following conditions; HRD1 KD (green, n = 7), SCR control (SCR, grey, n = 7), or 
shRNAs targeting both HRD1 and Tomo-1 (2KD, blue, n = 8). F, Cumulative frequency 
distributions of spine density from above conditions. All data presented as population 
mean ± SEM, with n# defined as individual dendrites or neurons from independent 
culture dishes. Statistical significance (#, p<0.1; *, p < 0.05; **, p < 0.01), where 
indicated, was determined vs. SCR vector control using one-way ANOVAs with multiple 
comparisons of the mean or Kolmogorov-Smirnov tests of cumulative frequency 
distributions.
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CHAPTER III 
Tomosyn-1 is ubiquitinated by HRD1 at multiple lysine residues 
 
3.1 Abstract 
 Tomosyn-1 (Tomo-1), a soluble, R-SNARE domain-containing protein, elicits 
significant inhibitory effects in secretory cells, including on neurotransmitter-containing 
synaptic vesicle release in central neurons. It has recently been identified that Tomo-1 
is subject to ubiquitination by the E3 ligase HRD1 in neurons, leading to its proteasomal 
degradation, and ultimately decreasing Tomo-1 levels to influence the density of 
postsynaptic dendritic spines in hippocampal neurons. However, the specific sites of 
Tomo-1 ubiquitination have yet to be identified. Here, via tandem mass spectroscopy, 
we found that mammalian m-Tomo-1 protein is specifically ubiquitinated at twelve 
independent lysine residues by HRD1 in vitro. A number of these newly identified Tomo-
1 ubiquitination sites are at or near other known sites of post-translational modification, 
including phosphorylation and SUMOylation. Furthermore, our Tomo-1 isoform and 
homologue domain evaluation and antibody-based regional targeting of Tomo-1 from 
neuronal lysate has indicated four lysine residues which are highly likely to be 
ubiquitinated in vivo. Though generation and evaluation of a non-ubiquitinateable Tomo-
1 mutant construct was inconclusive, our results have confirmed that Tomo-1 is indeed 
ubiquitinated by HRD1 and further informs the growing body of research indicating 
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Tomo-1 is a likely target for UPS-mediated degradation toward synaptic plasticity 
induction. 
 
3.2 Introduction 
The ubiquitination and degradation of synaptically active proteins has emerged 
as a vital cell biological mechanism by which neurons refine synaptic connections 
during development and modulate synaptic activity and plasticity in adult organisms (1). 
Protein degradation by the ubiquitin-proteasome system is completely dependent upon 
the post-translational attachment of ubiquitin molecules to target substrates. This action 
occurs via the concerted efforts of over 1,000 proteins in humans (2), ubiquitinating 
thousands of proteins at tens-of-thousands of individual sites (3, 4). Furthermore, 
refined biochemical methods, such as linkage-specific ubiquitin antibodies, in 
combination with technological advances in large-scale proteomic data acquisition and 
analysis capabilities have rapidly increased our recognition of the complexity and 
physiological importance of the UPS. Mass spectrometry (MS)-based methods, most 
commonly consisting of the tryptic digestion of ubiquitin within protein samples and the 
analysis of resulting di-glycine-containing peptides, have had a substantial impact on 
the study of ubiquitination (5). This approach facilitates the comprehensive annotation 
and quantification of specific protein ubiquitination sites from a wide variety of upstream 
sample generation techniques. Once a substrate protein has been identified, MS is one 
tool allowing for the targeted analysis of its ubiquitination and proteostasis 
characteristics. 
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In Chapter 2 of this dissertation the research identified that Tomo-1 proteostasis 
in neurons is at least partially controlled by the E3 ligase HRD1, including initial 
indications of a downstream functional effect on synaptic morphology (6). These results 
also confirmed, with in vitro assays utilizing purified components and in vivo assays 
from neuronal culture, that Tomo-1 is ubiquitinated and degraded. As such, the 
identification of Tomo-1 ubiquitination site(s) is of high priority. 
The objectives of this series of experiments were three-fold; confirm Tomo-1 
protein is ubiquitinated, identify which lysines of Tomo-1 are targeted and ubiquitinated 
by HRD1, and with this information generate a non-ubiquitinateable Tomo-1 mutant 
construct. Success in identifying the specific Tomo-1 residues subject to ubiquitination 
would promote future investigations to rigorously define downstream physiological 
effects on synaptic plasticity, including contributions of the observed dendritic spine 
density effects of Tomo-1 protein level. Furthermore, application of this mutant protein 
could allow for a non-ubiquitinateable Tomo-1 rescue expression paired with 
endogenous WT Tomo-1 KD. Here we review our investigations targeting identification 
of HRD1 ubiquitination sites of mammalian m-Tomosyn-1 protein. 
 
3.3 Results 
The initial discovery of Tomosyn resulted from a Syntaxin1a pull-down assay 
from the cytosol of rat cerebrum (7). It was later determined that Tomosyn is expressed 
by two genes, leading to Tomo-1 and Tomo-2 gene products (8). Tomo-1 and Tomo-2 
are subsequently subject to alternative splicing, resulting in a total of seven protein 
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isoforms (see Fig. 3.1A). The three Tomo-1 isoforms (s-, m-, and b-Tomo-1, for small, 
medium, and big) maintain a high level of conserved structure, with sequence 
differences found exclusively within its hypervariable domain (9). Evidence suggests the 
s- and m-Tomo-1 variants are brain-specific and highly enriched in synaptic regions of 
neurons. Furthermore, there are several reported post-translational modifications of m-
Tomo-1 within its hypervariable domain (see Fig. 3.1B), including protein kinase A 
(PKA) phosphorylation (10, 11) and SUMOylation (12) by PIAS (13). Notably, these 
post-translational modifications influence Tomo-1’s interaction with partner proteins as 
well as its functional effects on the fusion of synaptic vesicles and neurotransmitter 
release. For example, PKA phosphorylation at serine-724 reduces Tomo-1’s interaction 
with Syntaxin1, while PIAS-mediated SUMOylation at K730 did not appear to affect its 
Syntaxin1 interaction. However, Tomo-1 SUMOylation does apparently reduce its 
inhibitory actions (12). The conclusions from Chapter 2, that Tomo-1 is subject to 
ubiquitination by HRD1 for UPS-mediated degradation, led us to question if this could 
be another post-translational mechanism whereby Tomo-1 action is regulated in 
neurons.  
 
Confirmation of Tomo-1 ubiquitination by HRD1 and identification of specific lysine 
residues 
Testing the hypothesis that ubiquitination influences Tomo-1 function first 
required a more highly resolved examination of Tomo-1 ubiquitination than was reported 
via Western blots in Chapter 2. We implemented a tandem mass spectrometry strategy 
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for the confirmation and identification of specific ubiquitination sites of Tomo-1. During 
ubiquitination, a ubiquitin molecule is covalently conjugated to a specific amino acid of 
the target protein substrate, most commonly a lysine residue. Following m-Tomo-1 
protein production and purification from HEK293T cells and in vitro ubiquitination by 
HRD1 we evaluated trypsin-digested Tomo-1 protein samples for positive identification 
of ubiquitinated lysine residues by mass-to-charge (M/z) shifts in recurring peptide 
fragments containing di-glycine motifs (see Fig. 3.1C for example M/z chromatogram). 
Positive hits were manually verified and compared with the Uniprot rat protein database 
and results yielded 12 unique ubiquitination sites of m-Tomo-1. 
 
Modeling and probability-ranking Tomo-1 ubiquitination sites 
The twelve identified ubiquitination sites are sequentially displayed in the 
schematic diagram of a linear Tomo-1 protein in Fig. 3.2A, four of which reside within 
the hypervariable domain. Notably, two of these ubiquitination sites are identical to or 
directly adjacent to sites of other known PTMS (SUMOylation at K730 and 
phosphorylation at S724, respectively). This may be of future consequence, as the 
interplay between PTMs is becoming widely recognized as a diverse mechanism for the 
biomolecular control of synaptic protein function. For example, the targeting of a site for 
ubiquitination and therefore likely inactivation or degradation, following a nearby 
phosphorylation event (14, 15). Relatedly, one study of exogenously expressed Tomo-2 
protein showed that serine-to-alanine replacement of all 11 phosphorylatable residues 
inhibited its ubiquitination by HRD1, ultimately reducing its proteasomal degradation in 
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HEK293 cells (16). Given numerous potential SUMOylated and ubiquitinated lysine 
residues are proximal to phosphorylatable serine residues within and around the 
hypervariable domain of Tomo-1 and Tomo-2, both are likely candidates for regulation 
by phosphorylation events (13, 16). 
Following the confirmation of Tomo-1 ubiquitination at specific, but numerous, 
lysine residues we next mapped their locations within the structure of Tomo-1 using 3D 
protein modelling software informed by the empirically determined structure of a Tomo-1 
protein orthologue in another species. We then used this predicted structure to evaluate 
accessibility and solubility ratings of each site, in addition to the confidence intervals 
generated and frequency of occurrence of each site from the MS/MS results. These 
analyses led to four identified lysines judged to have the highest probability of being 
ubiquitinated within our samples. These four sites are labeled and displayed in-line with 
the 3D Tomo-1 ribbon structure model shown in Fig. 3.2B, two of which reside within its 
hypervariable domain. 
 
Generation of 12xKR non-ubiquitinateable mutant Tomo-1 
Following determination of a dozen Tomo-1 ubiquitination sites mediated by 
HRD1 we intended to validate their physiological significance by creating a 
ubiquitination-null mutant protein. This approach would allow using a KD and rescue or 
KI Tomo-1 null mutant approach for the targeted disruption of endogenous Tomo-1 
turnover in neurons and subsequent examination of how Tomo-1 degradation influences 
its function and potential influence on neuronal physiology. To generate the construct 
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encoding a non-ubiquitinateable mutant Tomo-1 each identified lysine was replaced 
with an arginine. A lysine-to-arginine (K-R) site mutation is commonly employed to 
inhibit the covalent attachment of ubiquitin while maintaining the potentially important 
negatively charged amino acid residue at the site. We designed custom oligonucleotide 
primers to specifically target each site and introduce a point mutation (A-G) in the 
plasmid sequence and subsequently convert each lysine to an arginine during 
translation. To do so we utilized a commercially available cloning system to perform 
site-directed mutagenesis on the WT m-Tomo-1 contained within the tandem affinity-
tagged construct used in Chapter 2, which was also the same construct used for in vitro 
assays and mass spectrometry. Performing iterative mutagenesis reactions allowed for 
the creation of plasmids encoding Tomo-1 with each lysine mutated to an arginine 
individually in conjunction with a single construct containing all 12 K-R mutations 
(12xKR Tomo-1). 
 
Promiscuity in ubiquitination of the 12xKR Tomo-1 
All constructs were fully sequenced and aligned to WT to ensure the intended 
nucleotide identities (fully WT, except for the single point mutations) and then expressed 
as previously described for WT Tomo-1 production. The 12xKR Tomo-1 protein was of 
high purity and maintained its apparent mass of ≈ 135kD, as indicated via SDS-PAGE 
followed by coomassie staining and displayed in Fig. 3.2C. However, the 12xKR Tomo-
1 mutant only showed an approximate 50% decrease in ubiquitination (Fig 3.2D), 
following an in vitro ubiquitination assay described fully in Chapter 2. It is at present 
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unclear if HRD1 acts in vitro to promiscuously ubiquitinate Tomo-1 in vitro, perhaps due 
to the concentration of either protein, lack of regulatory HRD1 co-factors, or other assay 
parameters (e.g. temperature, time) and limitations. Alternatively, because target lysines 
were no longer present in the 12xKR assays, we cannot rule out opportunistic 
ubiquitination events catalyzed by HRD1, for example, the addition of ubiquitin 
molecules to the nearby non-mutated lysine residues still present in the 12xKR amino 
acid sequence. 
Though attempted, anti-Tomo-1 IP from neuronal samples yielded too little 
Tomo-1 for identification of in vivo Ub sites via MS/MS and samples also contained non-
specific co-IP levels of unrelated proteins. Notably, we have now generated lentiviral 
constructs expressing the WT and the 12xKR Tomo-1 proteins in a YFP-containing 
vector for follow-up testing and use in neurons, including repeating ubiquitination assays 
and resubmission for MS/MS analysis. Future work will now be better-equipped to 
minimize variation in sample yield and to generate samples in vivo in neuronal culture, 
where the full complement of HRD1 interacting partners and cell biological processes 
will presumably be unhindered. This would also allow for finer scale manipulations 
including increasing or decreasing neuronal activity via electrophysiological and 
pharmacological approaches. Once the 12xKR Tomo-1 has been fully evaluated it will 
be crucial to confirm the specificity of any findings using the constructs already 
generated and expressing Tomo-1 with the single K-R mutations for attribution of effects 
to specific lysine(s). 
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Antibody/antigenic sequence-based analysis of Tomo-1 ubiquitination sites 
Though limited by protein yields and prevalence of ubiquitination in the series of 
experiments utilizing the 12xKR mutant, we attempted complementary methods of 
determining the specificity and implications of Tomo-1 ubiquitination in vivo. In 
conjunction with the homology modeling of 3D Tomo-1 protein structure and mapping of 
identified ubiquitination sites we made use of multiple specific antibody-based 
immunoprecipitation approaches to inform our interpretations of these results. Figure 
3.3 displays an example Western blot of lysate and IP samples probed for Tomo-1 and 
HRD1 (Fig. 3.3A) and conjugated ubiquitin (Fig. 3.3B). For this set of experiments, we 
made use of the varying antigenic sequences of various commercially available anti-
Tomosyn antibodies (for antigenic target sequences see Fig. 3.2A, bottom). Tomo-1 
and Tomo-2 were each IPd from the same hippocampal neuronal culture lysate 
samples and subjected to SDS-PAGE. Upon protein denaturing in-gel followed by 
transfer to nitrocellulose the membranes were probed with a pan-Tomo (anti-Tomo1/2) 
antibody for detection. Two experimental conditions were tested in culture; a 4-hour 
treatment with the proteasome blocker MG132 and the cell-permeable, broad-spectrum 
DUB inhibitor PR-619 to non-specifically but heavily drive the buildup of ubiquitinated 
Tomo-1, and a DMSO vehicle control treatment for baseline comparison. 
Strikingly, following the pharmacologically-driven and acute increase in the level 
of ubiquitinated Tomosyn in hippocampal neurons, the IP of each variant was drastically 
reduced. This effect was apparent as a lack of Tomosyn bands in the treated condition 
and the concurrent loss of conjugated ubiquitin banding at the apparent mass of 
	 119	
Tomosyn. It appears that the treated condition was indeed enriched in ubiquitinated 
proteins (see input sample lanes) but this Tomo-1 had a lack of affinity during 
subsequent antibody IP. The unbound fractions, though substantially diluted for the in-
solution binding period following sample mass and volume equalization between 
conditions, each show what appear to be elevated Tomosyn levels vs. vehicle control 
unbound samples (Fig. 3.3A). 
 
3.4 Discussion 
Chapter 3 of this dissertation has identified multiple Tomo-1 sites specifically 
ubiquitinated by HRD1 in vitro, further justifying the necessity of evaluating post-
translational modification of Tomo-1 in examination of its mechanistic implementation of 
inhibitory and morphological actions within the nervous system. Furthermore, this work 
has provided an additional tool for use in this evaluation, namely twelve individual (see 
Fig. 3.2A) and one total (12xKR) ubiquitination site mutant Tomo-1 constructs. 
Application of this mutant protein could allow for a non-ubiquitinateable 12xKR Tomo-1 
rescue expression paired with endogenous WT Tomo-1 KD to aide in determination of 
the exact influence of Tomo-1 ubiquitination at these specific sites. In addition, while 
undertaking the research overviewed in Chapter 3 we have also inserted the full 12xKR 
Tomo-1 construct into the lentiviral YFP vector utilized in the Chapter 2 studies and 
began initial testing of its increased neuronal expression and greater yield during 
purification. Relatedly, its WT counterpart was also created and will facilitate repeating 
MS/MS evaluation of neuronal samples acquired in vivo.  
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The maintained 50% ubiquitination of 12xKR mutant Tomo-1 following in vitro 
assay may also be difficult to avoid in vivo without the inclusion of complementary 
techniques for compartment-specific study, such as fluorescence imaging or synaptic 
sample enrichment strategies, which would allow for further specification of where 
Tomo-1 is being regulated. A dual approach such as this would also lower the likelihood 
of any localized (e.g. pre- or post-synaptic, membrane-bound, phosphorylated) Tomo-1 
effects from being occluded by the total cellular Tomo-1 content. It is currently 
presumed that the fraction of ubiquitinated Tomo-1 at any given time in vivo is far lower 
than the total, both due to potential rapid degradation of poly-ubiquitinated synaptic 
proteins (17, 18) and the proportion of synaptic vs. the total cellular Tomo-1 (see 
Chapter 2). Success in identifying the specific Tomo-1 residues subject to ubiquitination 
in vivo would promote future investigations to rigorously define downstream 
physiological effects on synaptic plasticity, including contributions of the observed 
dendritic spine density effects of Tomo-1 protein level outlined in Chapter 2.  
The decrease in Tomo-1 IP following upregulated ubiquitination in vivo likely 
resulted from its antigenic sequence, which spans the entirety of the Tomo-1 
hypervariable domain. This is informative because it appears that the treated condition, 
enriched in ubiquitinated proteins as evidenced by comparing input samples between 
the respective conditions, has a greatly-reduced affinity for the specific antibody used 
for IP. The implication underlying the loss of Tomosyn IP following ubiquitination is 
further evidence supporting the hypothesis that Tomo-1 is ubiquitinated within its 
hypervariable domain, where other PTMs are known to occur. Given a single ubiquitin is 
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≈ 7.8kD in size and poly-ubiquitination, typically of 4+ linked moieties, it is not 
unreasonable to hypothesize that a ≥ 31.2kD protein complex covalently attached to the 
target sequence of the Tomo-1 antibody disrupts their affinity for each other. 
Conversely, the WT and 12xKR Tomo-1 constructs tested in vitro and for MS/MS were 
purified from HEK293T lysate samples via their capacity for a streptavidin-biotin pull-
down mechanism (see methods). The affinity tags of these constructs were fused to the 
C-terminus of the Tomo-1 protein in both cases, avoiding any potential disruption due to 
ubiquitination of their hypervariable regions. These data further support the utilization of 
the newly generated, affinity-tagged Tomo-1 WT and 12xKR lentiviral constructs in vivo 
in neurons for future experiments. 
 
3.5 Materials and Methods 
Animals 
All animal handling procedures are approved by and in full compliance with the 
regulations of the University Committee on Use and Care of Animals of the University of 
Michigan, in addition to the National Institutes of Health guidelines. 
 
Antibodies 
Affinity-purified Rb anti-Tomosyn-1 polyclonal antibody (catalog no. 183103), 
affinity-purified Rb anti-Tomosyn-2 polyclonal antibody (catalog no. 183203), and 
affinity-purified Rb anti-Tomo-1/2 (pan-Tomo) antibody (catalog no. 183003) were from 
Synaptic Systems (Göttingen, Germany). The Ms anti-b-actin monoclonal antibody 
	 122	
(clone AC74, catalog no. A2228) was from Sigma-Aldrich (St. Louis, MO). The Rb anti-
HRD1 polyclonal antibody (catalog no. 13473-1-AP) was from ProteinTech (Chicago, 
IL). The Ms anti-conjugated-ubiquitin monoclonal antibody (clone FK2, catalog no. BML-
PW8810) was from Enzo Life Sciences (Farmingdale, NY). For western blots, IRDye 
800CW-conjugated goat anti-mouse IgG H+L (catalog no. 926-68021) and IRDye 
680LT-conjugated goat anti-rabbit IgG H+L (catalog no. 926-32210) fluorescent 
secondary antibodies were from Li-Cor Biosciences (Lincoln, NE). 
 
Cell Culture and Transfections 
Results from Chapter 3 were obtained from dissociated rat hippocampal neuronal 
cultures (prepared, treated, and lysed as described in Chapter 2) following in vitro 
culture for up to 5 weeks prior to experimentation, or HEK293T cells (prepared, 
transfected, and lysed as described in Chapter 2). 
 
12xKR Tomo-1 mutant construct generation 
All forward and reverse (anti-sense) primers for PCR-induced lysine-to-arginine 
mutations for the 12 indicated lysines of the rat m-tomosyn-1 coding sequence (NCB 
accession # NP_110470.1) were specifically designed using the free online tool offered 
by Agilent, which can be found at: 
https://www.genomics.agilent.com/primerDesignProgram.jsp. Primer sequences were 
then ordered from and generated by Integrated DNA Technologies (IDT) as custom 
oligonucleotide sequences. Primers were reconstituted according to manufacturer 
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specifications in molecular biology-grade water. Primers were then used in the 
QuikChange II XL (Agilent) protocol for the PCR reactions according to manufacturer 
specifications. Using the double-stranded DNA template of the Gateway rat m-Tomo-1 
plasmid outlined in Chapter 2 methods. PCR products were Dpn1 digested to remove 
parental DNA and transformed into XL10-Gold E. coli according to protocol. 
Transformants were streaked onto antibiotic-selective LB-agar plates and grown 
according to protocol prior to DNA preps. Endo-free Maxi preps (Qiagen) were then 
completed to yield high-purity plasmid DNA samples, which were fully sequences at the 
University of Michigan DNA Sequencing Core and stored at -20C until use. 
 
Drugs 
The following chemicals were used in Chapter 3, as noted: DMSO (Life 
Technologies, catalog no. D12345), MG132 (Cayman Chemicals, catalog no. 
10012628), PR-619 (Tocris, catalog no. 4482). Protease inhibitor cocktail minus EDTA 
(Roche, catalog no. 11580800) was added to the lysis and IP buffers at twice the 
manufacturer’s recommended concentration. 
 
Immunoprecipitation of Endogenous Tomosyn-1 and HRD1 from Hippocampal Neuronal 
Culture 
Immunoprecipitation of endogenous protein from cultured hippocampal neurons 
was performed using either the Tomo-1-specific or Tomo-2-specific antibodies noted 
above by pre-binding 2μg antibody to 50μL protein A magnetic dynabead slurry (Pierce, 
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catalog no. 88845) per 35mm dish in 100mM Na-phosphate buffer (pH 8.0) containing 
(mM): 75 Na2HPO4 and 25 NaH2PO4. Cultures were lysed and collected in non-
denaturing lysis buffer (pH 7.5) containing (mM): 50 NaCl, 25 Tris, 2 MgCl2, 1 CaCl2, 
0.5% NP-40, and 2x recommended concentration of complete EDTA-free protease 
inhibitor cocktail. Samples were then equalized for total protein concentration (1-
3μg/μL) and sample volume (100-300μL) prior to incubation with the conjugated beads 
for one hour at 4°C. The samples were then rinsed in lysis buffer and boiled in 1x SDS 
sample buffer for five minutes before being loaded for PAGE and western blotting. 
 
In Vitro Ubiquitination Assay 
The Gateway rat m-Tomosyn-1 construct noted above was used to express WT 
or 12xKR mutant Tomo-1 in HEK293T to encourage proper post-translational 
modification and 3-dimensional protein structure prior to experimental procedures. Cells 
were seeded at 50% confluence from liquid nitrogen stocks in 10cm cell culture dishes 
for ≈ 16 hours and serum-starved in 10mL Opti-MEM (Gibco catalog no. 31985) for one 
hour prior to transfection. Transfection occurred using 25μg plasmid DNA and 25μL 
Lipofectamine 2000 (Invitrogen, catalog no. 1166809) in 10mL Opti-MEM, per dish, for 
five hours under standard incubator conditions before standard HEK cell medium 
replacement. 48-72 hours following transfection the cells were lysed under non-
denaturing conditions in lysis buffer containing (mM): 100 Tris, 100 KCl, 0.2 EDTA, 1.5 
MgCl2, 0.01 pepstatin-A (Sigma, catalog no. P5318) and protease inhibitor cocktail 
minus EDTA (Roche) at 2x recommended concentration. Lysates were then subjected 
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to 3 freeze-thaw cycles using liquid nitrogen and centrifuged at 3,000xG for 10 minutes 
for de-nucleation. NP-40 was added to the lysate supernatants to a final concentration 
of 1% v/v. Lysates were then incubated with streptavidin-agarose beads (Invitrogen, 
catalog no. S951) for three hours at 4°C to purify the biotinylated epitope-tagged m-
Tomo-1 fusion construct. Final purity and protein concentration were quantified using a 
serial dilution vs. BSA standard on a SimplyBlue-stained SDS-PAGE gel. 
For use in ubiquitin reactions, 2μg purified Tomo-1 bound to the streptavidin-
agarose beads was suspended in assay buffer containing the following (mM): 100 Tris, 
10 MgCl2, and 0.2 DTT (Invitrogen, catalog no. 15508-013) and subjected to the 
following reaction conditions at 37°C for 45 minutes with mixing (E3Lite Ubiquitin Ligase 
Kit, catalog no. UC101, LifeSensors, Malvern, PA): 20μg/mL wild-type human ubiquitin 
(catalog no. SI201), 10nM UBE1 (catalog no. UB101), 100nM UBE2D2 (catalog no. 
UB207H), 250nM HRD1 (catalog no. UB307), 200μM ATP (catalog no. A50-09-200, 
SignalChem, Richmond, BC, Canada). 
 
Mass Spectrometry 
Mass spectrometry (MS) analysis of HEK293T lysate samples containing affinity-
purified Tomo-1 protein was conducted by the University of Michigan Proteomics 
Resource Facility (PRF, Ann Arbor, MI). Samples were submitted after in vitro 
ubiquitination reaction samples were separated on poly-acrylamide gels and proteins 
were visualized in-gel with SimplyBlue SafeStain (Invitrogen, Cat. No. LC6060), 
according to the manufacturer’s protocol. The PRF conducted in-gel digestion followed 
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by identification of ubiquitination sites via di-glycine indicators and site mapped. Trypsin 
digestion of excised SimplyBlue-stained protein bands beginning at the ≈ 135kDa 
Tomo-1 protein size and greater allowed peptides to be resolved on a nano-capillary 
reverse phase column and subjected to a high-resolution, linear ion-trap mass 
spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific). The full mass spectrometry 
scan was collected in Orbitrap (resolution 30,000 at 400 m/z), and data-dependent 
MS/MS spectra on the 12 most intense ions from each full MS scan were acquired. 
Proteins and peptides were identified by searching acquired data against the UniProt rat 
protein database, appended with decoy (reverse) sequences, using the 
X!Tandem/Trans-Proteomic Pipeline (TPP) software suite. All proteins identified with a 
ProteinProphet probability of >0.9 (FDR < 1%) were accepted. Spectral matches to 
ubiquitinated peptides were manually verified by the PRF. 
 
Protein Domain Comparison and 3-Dimensional Protein Modeling 
Tomo-1 and Tomo-2 splice isoforms were aligned from the following NCB 
accession numbers (in order s-, m-, b-Tomo-1, s-, m-, b-, xb-Tomo-2; NP_848036.1, 
NP_110470.1, NP_848035.1, NP_001108083.1, NP_001108085.1, NP_001108084.1, 
NP_766028.2). Tomo-1 3D structural modeling was generated from the FASTA CDS of 
rat m-Tomo-1 (NCB accession NP_110470.1) with I-TASSER (Iterative Threading 
ASSEmbly Refinement) via protocol (19). 
 
Western blotting 
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SDS-PAGE gels were wet-transferred onto nitrocellulose membranes at 10V for 
1.2 hours and blocked in non-mammalian Odyssey blocking buffer (Li-Cor Biosciences, 
Lincoln, NE, catalog no. 927-40000). Blocking, primary antibody, and secondary 
antibody incubations were all performed for 1 hour at room temperature and were rinsed 
3x for 5 minutes each in PBS + 0.1% Tween-20 (PBS-T) between incubations. All 
primary antibodies were used at a 1:1,000 dilution in PBS-T for western blotting, except 
for the following: anti-b-actin (AC74) 1:8,000 and anti-ubiquitin (FK2) 1:250. All 
secondary antibodies were used at a 1:15,000 dilution in PBS-T. Western blot images 
were collected with an Odyssey CLx Infrared Imaging System (Li-Cor model no. 9120) 
at 84µm resolution in high quality mode and within the linear range of exposure. 
Fluorescence density was quantified with the open-source ImageJ software including 
the FIJI imaging suite (20) and the gel analyzer plugin. 
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Figure 3.1: Tomosyn domains, splice isoforms, and post-translational 
modifications. 
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Figure 3.1: Tomosyn domains, splice isoforms, and post-translational 
modifications. 
 
A, Aligned Tomo-1 and Tomo-2 protein splice isoforms indicating relative sizes, 
conserved domains, and known phosphorylation sites. B, Table outlining known PTMs 
of Tomo-1 and each corresponding upstream kinase, SUMO ligase, and ubiquitin 
ligase. C, Example chromatogram generated from tandem mass spectrometry analysis 
of affinity-purified Tomo-1 protein sample. Graph peaks indicate the charge shift of post-
translationally modified protein fragments following enzymatic digestion.  
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Figure 3.2: Determination of Tomo-1 ubiquitination sites and lysine-arginine 
mutations. 
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Figure 3.2: Determination of Tomo-1 ubiquitination sites and lysine-arginine 
mutations. 
 
A, Linear map diagrams of Tomo-1, outlining its various protein domains, the 12 
ubiquitination sites empirically determined by tandem mass spectrometry analysis, and 
the manufacturer-provided antigenic sequences of the anti-Tomosyn antibodies used in 
this study. B, I-TASSER (Iterative Threading ASSEmbly Refinement) program 3-
dimensional ribbon structure model of rat m-Tomo-1 protein (cyan), including the four 
lysine residues rated as having the highest probability of being ubiquitinated (pink). The 
four highest probability ubiquitination sites were determined using confidence intervals 
calculated from the mass spectrometry data, frequency of occurrence, and accessibility 
ratings from the modeled 3-dimensional structure of m-Tomo-1. C, 12xKR Tomo-1 
protein subjected to SDS-PAGE followed by coomassie staining indicating maintained 
WT apparent molecular mass and high purity yield. D, Histogram quantifying an in vitro 
ubiquitination assay on the 12xKR Tomo-1 mutant shows an approximate 50% 
decrease in ubiquitination when normalized to paired WT Tomo-1 control reaction. 
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Figure 3.3: Ubiquitination of Tomo-1 inhibits its antibody affinity. 
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Figure 3.3: Ubiquitination of Tomo-1 inhibits its antibody affinity. 
 
A-B, Example Western blot of lysate, unbound, 3rd wash, and Tomo-1 and Tomo-2 IP 
samples from hippocampal neuronal lysates following 4-hour DMSO vehicle or 50µM 
MG132 + 10µM PR-619 treatment. Blots were probed with pan-Tomo (Tomo-1/2) and 
HRD1 antibodies (part A) and a conjugated ubiquitin antibody (part B). 
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CHAPTER IV 
Discussion: Targeted degradation: Pre- and post-synaptic effects on structural 
and functional plasticity 
 
Collectively, the results acquired in completing this dissertation suggest that the 
SNARE protein Tomo-1 is a novel and specific target of UPS-mediated proteostatic 
regulation (see overview Fig. 4.1), and furthermore, that modulation of Tomo-1 protein 
level via this mechanism underlies the induction of structural and functional plasticity 
within the nervous system. 
Our present characterization of the UPS-dependent regulation of Tomosyn 
furthers the field in that: it is the first reported identification of Tomo-1 ubiquitination and 
proteostasis regulation by the UPS, it identifies consequential functional effects of this 
regulation in live neurons, and it is the first report of morphological plasticity as a 
downstream effect of Tomo-1 regulation. Additionally, this is the first examination of an 
HRD1/Tomo-1 interaction, both biochemically and compartmentally, in neurons. 
Furthermore, this was the first examination of HRD1 in primary neurons, confirming it as 
a key regulator of both Tomo-1 proteostasis and Tomo-1’s consequential effects on 
dendritic morphology. Additionally, the novel PLA results indicate a potential local 
regulation of Tomo-1 by HRD1 at relevant subcellular regions, perhaps at synapses. 
Relatedly, our in vitro ubiquitination assays of Tomo-1 are the first reported, as are the 
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twelve ubiquitination sites we identified via mass spectrometry. These sites provide 
an initial characterization of the biochemical mechanisms underlying Tomo-1 
degradation, and thus provide the ability for more targeted examination. The Tomo-1 
antibody affinity variation following proteasome and DUB inhibition in neurons, further 
informed by the isoform and 3D protein structure modeling, hint that some of these sites 
are likely ubiquitinated by HRD1 in vivo. Lastly, the in vitro assays yield an initial 
estimation for the concentration-dependence of Tomo-1 ubiquitination by HRD1. 
Previous characterization of HRD1 focused on fibroblasts (1, 2) and the related 
Neuro2a (3), COS-1 (4), and SHSY5Y (5, 6) cell lines. Although these studies made use 
of cells that are neuron-like in some respects, prior to the studies of this dissertation it 
was completely unknown how HRD1 acts within individual primary neurons to influence 
their physiology and morphology. 
Work from many labs has suggested that neuronal activity induces retrograde 
messengers from postsynaptic neurons to influence their presynaptic counterparts and 
tune synaptic strength (7). For example, postsynaptic upregulation of mTORC1 activity 
(8, 9), and the closely associated signaling molecules BDNF (10) and phosphatidic acid 
(PA) (11), prompts the presynaptic facilitation initiated by decreased excitatory input, a 
homeostatic mechanism (12). Though much of the work on mTORC1 has focused on its 
modulation of the initiation of protein translation (13, 14), its upregulation of postsynaptic 
BDNF also acts as a retrograde signal to the presynaptic neuron and requires 
proteasomal activity to induce compensatory homeostatic plasticity (10, 15), LTP (16), 
and LTD (17). Thus, altering postsynaptic excitatory inputs is likely to drive activity-
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dependent plasticity in presynaptic release through the initiation of a coordinated 
adaptation in the local translation and targeted degradation of synaptic regulatory 
proteins (18). It is of specific interest that this proposed mechanism of plasticity 
induction is not simply a rebalancing of opposing constitutive/steady-state mechanisms 
already in effect within individual pre- or post-synaptic neurons or terminals. It also 
requires coordinated physiological adaptations between distinct, but synaptically-
coupled neurons. Our present findings further posit that this trans-synaptic mechanism 
implements a rebalancing of protein turnover rates via the upregulation of targeted 
degradation, that this is crucial for at least one type of morphological plasticity induction, 
and this may occur independently of or alongside known translational control 
mechanisms. 
There is a growing body of evidence underscoring the importance of targeted 
synaptic protein degradation in neuronal physiology and plasticity (19-22). Much of this 
work focuses on the turnover and trafficking of neurotransmitter receptors (23-27) and 
scaffolding proteins (28, 29) of the postsynaptic compartment. However, presynaptic 
degradative mechanisms are becoming increasingly elucidated (30, 31). Notably, 
proteasomal degradation of the vesicle priming factor RIM by the E3 ligase SCRAPPER 
has been reported to mediate presynaptic activity and plasticity (32, 33). However, 
SCRAPPER-dependent RIM degradation primarily affects miniature and spontaneous, 
but not evoked, release (32, 34). Furthermore, as a critical vesicle priming factor, RIM 
levels are positively correlated with the probability of release. Therefore, if RIM were the 
primary presynaptic target of an mTORC1/BDNF-induced increase in proteasomal 
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degradation it would be expected to counter the observed upregulation of presynaptic 
activity following AMPAR inhibition-mediated homeostatic plasticity induction. Thus, 
BDNF-mediated increases in ubiquitination and proteasomal degradation, and the 
consequential increase in presynaptic output, strongly suggest that the target of 
degradation underlying homeostatic induction is a negative regulator of neurotransmitter 
release. The identity of the presynaptic inhibitor targeted by retrograde signaling from 
the postsynaptic neuron to facilitate homeostatic plasticity is yet to be identified. Our 
findings highlight Tomo-1 as a high-probability presynaptic inhibitory candidate for this 
presynaptic inhibitor. 
Tomo-1 exhibits inhibitory action in secretory cells, including central (35) and 
SCG neurons (36), chromaffin cells of the adrenal medulla (37), ß-cells of the pancreas 
(38), as well as the PC12 (39, 40) and CHO (41) secretory cell lines. Relatedly, 
Tomosyn is found to be colocalized to presynaptic terminals alongside numerous other 
proteins that are important for the exocytic process, including Syntaxin1a, VAMP2, 
Bassoon, Synaptophysin, and vGluT1 (36, 42-45). This is notable because it suggests a 
conserved need, across organ systems and species, for a brake to balance facilitative 
and constitutive secretory mechanisms. Interestingly, Tomo-1 protein has also been 
found to associate with synaptic vesicles (42-44) and the plasma membrane of insulin-
secreting adipocytes (46), bovine adrenal chromaffin cells (37), and the PC12 cell line 
(37, 40). Furthermore, Tomo-2 was identified in dendrites of mammalian hippocampal 
neurons (47). This diversity in Tomo-1 expression highlights the need for a more 
complete understanding of its actions and mechanisms beyond that which is currently 
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known regarding its presynaptic inhibition. An open question following the finding of 
postsynaptic Tomosyn by Barak et al. (47) is how it may act there to influence synaptic 
physiology or plasticity. Indeed, we have here further identified that Tomo-1 colocalizes 
with the postsynaptic scaffolding protein PSD95 in hippocampal neuronal culture and is 
also expressed and serves a regulatory role within dendritic spines. This finding is 
significant because, not only is it a new characterization of Tomo-1 expression, we have 
further recognized a mechanism by which the Tomo-1-dependent density of dendritic 
spines is regulated, namely by HRD1. At present however, a physiological effect of 
spine density regulation remains elusive. 
Currently identified inhibitory mechanisms of Tomo-1 stem from its C-terminal 
SNARE domain competitively inhibiting VAMP and Munc18 from binding with reactive 
Syntaxin1a in vitro (48, 49), in C. elegans (43), in chromaffin cells (37), and in SCG 
neurons (49). However, its N-terminal WD40 repeat domain also appears to have the 
capacity for sequestering SNARE complexes (50). Ultimately, Tomo-1 decreases the 
priming and fusion of RRP vesicles in neurons (50-52). This biochemically-driven model 
casts Tomo-1 as a rather passive inhibitor of vesicle priming and concomitant release. 
However, the integration of present findings supports the addition of a more functional 
understanding of how Tomo-1 influences synaptic physiology and plasticity. The 
completely novel finding that Tomo-1 protein level is regulated by the UPS positions it 
as the prime candidate inhibitory presynaptic effector of the targeted retrograde action 
following activity-induced postsynaptic upregulation of mTORC1/BDNF. Furthermore, 
we are the first to identify effects of Tomo-1 on dendritic morphology, which occurred in 
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a SNARE domain-independent fashion. This promotes fresh consideration of the 
mechanisms by which Tomo-1 actions are implemented. 
There are reports of regulatory mechanisms contributing to the action of Tomo-1 
and orthologues, however most are still in reference to its inhibitory effects and/or its 
SNARE domain (49, 53-55). These include conformational changes of the tail domain 
influencing overall protein structure and binding affinity of Tomo-1 for partners such as 
VAMP (56), Munc13 (43), and Rab3 small GTPases (51, 57, 58). Our unique findings 
offer a shift in focus for identifying Tomo-1 regulatory mechanisms and their influence 
over neurotransmission. That is, we suggest additional consideration is warranted in the 
focus of Tomo-1 research – evaluation of the variations in intrinsic protein properties 
(such as conformation) and SNARE-specific mechanisms (and their influence on 
effector interactions) should also include thorough examination of upstream Tomo-1 
regulatory mechanisms. For example, the post-translational modification of Tomo-1 is 
becoming recognized as critical in contributing to the cell biological pathways sensing 
and rectifying neuronal activity (51) as well as those controlling the amount of Tomo-1 
present in neurons (59). Indeed, there are multiple reports from our lab and others 
indicating the importance of PTMs in regulating Tomosyn protein action, including 
SUMOylation (40, 60) and phosphorylation (36, 41, 51, 61). However, to date, there is 
only one report on the regulation of Tomosyn protein level. It was shown that 
exogenously expressed Tomo-2 protein degradation by HRD1 was facilitated following 
its phosphorylation in the heterologous HEK293FT cell line (61). The hypothesis that 
controlling Tomo-2 level has relevance in vivo was substantiated by the fact that 
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glucose-stimulated insulin secretion in pancreatic ß-cells significantly increased the rate 
of Tomo-2 turnover. 
Previous work on HRD1’s roles in primary cells centered around its non-
secretory ERAD processes and its gross localization to specific brain regions in mice 
(62-64) and the post-mortem brains of human AD patients (6, 65-67). Results presented 
herein exemplify the previously hypothesized, but largely unknown, significance of 
HRD1 action in the regulation of neuronal activity. Notably, one study employed the use 
of chemically-differentiated neurons from P19 cells following retinoic acid treatment to 
examine the effect of HRD1 in culture and determined HRD1 has neuroprotective 
effects in response to tunicamycin-induced ER stress and influences dendrite outgrowth 
during development (68). Our results build on this foundation by indicating a similar role 
in primary neurons and further indicate a mechanism by which the effects are mediated. 
The neurodevelopmental importance of HRD1 was initially identified because HRD1 null 
mouse embryos were found to be inviable due to death in utero (1). This result contrasts 
those from its orthologue, HRD1p, being dispensable in yeast. However, it is still an 
open question how HRD1 contributes to the development and integration of neurons 
and synapses, other than its regulation of Tomo-1 to control dendritic spine 
morphogenesis in mammalian excitatory neurons of the hippocampus. Relatedly, the 
mTORC1/BDNF pathway has been linked to morphological adaptations, such as those 
observed in postsynaptic dendritic spines during LTP induction (69, 70). In addition, it 
appears that LTP and homeostatic upregulation, though both utilizing postsynaptic 
mTORC1 and upregulated protein translation, can be induced by different cellular 
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mechanisms. Though many questions remain to be answered, our work suggests that 
the ubiquitination of synaptic proteins does not only alter presynaptic release and 
receptor cycling to modulate the strength of individual boutons, but also controls the 
number of synapses linking neurons into networks, as indicated by dendritic spine 
count. This evidence highlights the necessity for parsing out feed-forward- and 
feedback-based cellular mechanisms, most notably the UPS and its upstream 
activation, in the implementation of modulating synaptic morphology and plasticity. 
Overall, our findings fit with our initial hypothesis in the sense that we indeed found 
Tomo-1 to be under the control of the UPS in neurons. Furthermore, this level of control 
influenced cell morphology in a way we expect to contribute downstream of these 
increased synaptic locations. 
 
4.2 Limitations and Future Directions 
Chapter 2 
 The importance of the UPS in regulating protein levels through targeted 
degradation is widely recognized in eukaryotic cells. This is partially illustrated by the 
substantial number of human diseases related to alterations in proteostasis (71). 
However, careful examination of individual cell-types, tissue regions, physiological 
conditions, and activity parameters is further required to better understand how Tomo-1 
degradation affects neuronal function. The approaches utilized in acquiring Chapter 2 
data do not differentiate between hippocampal neuron sub-types, primarily due to the 
dissociated cell culture approach. However, a number of specific targeting approaches 
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were implemented to ensure results obtained on the UPS-mediated regulation of Tomo-
1 occurs in neurons and not glial cells, as outlined in the results and materials and 
methods sections therein. Due to the lack of identification of individual neuronal sub-
types, which are known to differentially express a plethora of important proteins and 
undergo varying forms of plasticity (72, 73), our conclusions are limited to those 
neurons which we were able to specifically resolve (general for biochemistry, pyramidal 
for imaging). Furthermore, it is at present unknown if any of the recognized effects also 
occur across developmental stages, such as the differentiation of neurons and the 
biogenesis and integration of dendrites and synapses. Data acquisition occurred 
between the noted timepoints in reference to animal age at primary cell harvesting as 
well as number of days in vitro following dissociation and plating. Greater resolution in 
how these degradation effects are differentially implemented by neurons during various 
stages of maturity and plasticity state requires careful examination of a repeated 
measures/timecourse approach. 
The high level of sequence and structural homology between the three Tomo-1 
splice isoforms in mammals (40, 74) is also a limiting factor to some degree, in that 
there are, at present, no commercially available isoform-specific antibodies. Therefore, 
it is unclear which isoforms of Tomo-1 may be preferentially targeted and regulated, 
including their localization, effector affinity, and resulting downstream effects. However, 
it is reported that the s- and m-Tomo-1 isoforms (for small and medium) are brain-
specific, as evidenced by RT-PCR of Tomo-1 mRNA, and highly enriched at synapses 
(35, 75). Relatedly, it is presently unknown if and how the related Tomo-2 protein may 
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act endogenously within these neurons. Tomo-1 and Tomo-2 have regions of 
overlapping and non-overlapping expression in the intact hippocampus likely also within 
individual compartments of various neurons (47). Therefore, there is the potential for 
differential expression, as well as supplemental, redundant, and/or competitive actions 
of Tomo-1 and Tomo-2 in mediating some of the results outlined in Chapter 2. Again, 
specific targeting of Tomo-1 was implemented wherever possible, with verified 
antibodies and proof-of-principal empirical testing, as described in the results and 
materials and methods sections. 
Resulting from the general limitations of the biochemical analysis of neuronal 
lysate samples, our ubiquitination studies do not allow for spatially resolving the 
subcellular regional location of Tomo-1 interaction with HRD1, its ubiquitination, nor its 
degradation. Notable exceptions include all fixed- and live-cell imaging experiments, 
including the proximity-ligation assay for Tomo-1/HRD1 interaction in situ. Otherwise, 
results generated in Chapter 2 cannot be specifically attributed to synapses, or even 
axons or dendrites, though given HRD1’s integral ER membrane localization, they are 
presumed to occur at subcellular regions with some sort of ER present. Therefore, the 
additional implementation of high-resolution imaging and biochemical enrichment 
strategies is a logical next step for further conclusions of this research topic. Imaging 
approaches, including Dendra2-Tomo-1 fusion protein expression via sparse 
transfection as in chapter 2, would allow for timelapse imaging of proteostasis while 
affording the additional control of tracking both translation and degradation rates with 
subcellular specificity. This approach could be expanded further in the implementation 
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of UPS-specific pharmacological manipulations, Tomo-1 disruptions including K-R 
ubiquitination mutations and loop domain deletions, and electrically- or chemically-
induced plasticity. Findings gathered from these experiments should yield additional 
insights into both how and where Tomo-1 is controlled during its action on synaptic 
activity and morphological plasticity. Further biochemical approaches and analyses are 
also warranted to probe the detailed mechanisms utilized in the proteostatic regulation 
of Tomo-1 and its relationship with effector proteins following post-translational 
modifications including ubiquitination and phosphorylation. For example, differential 
centrifugation and neuro/synaptosomes preparation would promote the identification of 
Tomo-1 ubiquitination sites in vivo from neurons under various conditions, which is 
critical to determining if the synaptic population of Tomo-1 is specifically targeted versus 
the total and could be carried out vis SDS-PAGE and mass spectrometry analyses. 
The study of Tomo-1 proteostasis is currently in its infancy. Indeed, there are 
no known in vivo variations of Tomo-1 protein expression level modulation reported in 
neurons with which to compare our novel HRD1-mediated observations. The 
importance of this consideration cannot be overstated, as numerous synaptic proteins 
are reported to have relatively long half-lives (76, 77), which can be drastically altered 
upon perturbing proteasomal activity (78). Furthermore, determination of steady-state 
Tomo-1 levels in specific brain regions, cell-types, specific activity paradigms, is needed 
to identify both the physiological scale of our observed Tomo-1 protein level changes, 
and consequentially, its relevance to tuning Tomo-1 level within that dynamic range. 
Relatedly, our interpretations of the proteasome activity-dependent alterations in Tomo-
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1 protein level rely on the assumption that the decrease in UPS activity is the primary 
cause of Tomo-1’s increased proteostasis. Although this is the most straightforward 
interpretation of the data, we did not empirically determine degradation rates 
themselves to identify specific changes. However, we do find increased Tomo-1 protein 
level upon inhibiting the E3 ligase HRD1 and by inhibiting the catalytic activity of the 
26S proteasome with two different pharmacological agents, adding specificity to this 
system. Nonetheless, the topic of neuronal and synaptic protein lifetimes has become a 
recent topic of quantitative investigation (77-78). Results appear to indicate that simple 
pharmacological treatments modulating the UPS can prompt unanticipated effects in 
protein production rates, in addition to degradation, which may confound our 
interpretation. It would be quite useful to now make relevant synaptic protein lifetime 
measurements. Indeed, there is evidence in the literature regarding the protein lifetime 
of Tomo-1 being quite extensive. Tomo-1 half-life was reported via stable isotope 
labeling with amino acids in cell culture (SILAC) to be approximately 94 hours, with an 
approximate 136-hour lifetime (76, supplemental data tables). Although protein 
biosynthesis rates themselves were not examined, the effects following use of 
proteasome inhibitors were found to be complementary to those of our HRD1 KD 
condition, which resulted in a specific increase in Tomo-1 protein in our similar 
hippocampal culture system. Thus, we hypothesize that KD of HRD1, as an E3 
targeting Tomo-1, to be more selective when compared to global pharmacological 
inhibition of the proteasome, especially given the rather acute 4-hour timescale of our 
proteasome blockade treatment. However, ultimately, an increase in Tomo-1 
	 148	
biosynthetic activity could be linked to reduced UPS-mediated degradation or actions of 
proteasome blockers and thus are limited in further conclusions. This requires empirical 
determination via complementary methods, which would allow for the specific influences 
of HRD1 interaction, ubiquitination, and proteasomal degradation on the gross and 
specific sub-populations of Tomo-1 to be evaluated under various physiologically-
relevant paradigms such as plasticity induction. 
Given that HRD1 is heavily reported to interact with numerous partner proteins in 
accomplishing its degradative tasks (79-81) it will be worthwhile to probe for the 
necessity and effect of these mechanistically-related adapting and stabilizing proteins. 
The present study did not determine if or which partner and effector proteins are 
required by or facilitate HRD1’s regulation of Tomo-1 levels in vivo, which will be 
required prior to examination of potential resultant changes in synaptic physiology. We 
did however identify which UPS-related proteins are minimally required for HRD1-
mediated degradation of Tomo-1 in vitro, which include the mammalian E1 UBE1, the 
E2 UBE2D2 (also known as UbcH5b), the E3 HRD1, mammalian Ubiquitin, and ATP. 
However, the HRD1 provided has the ER-transmembrane region deleted to inhibit 
potential aggregation. Furthermore, critical regulation of total or specific HRD1 target 
substrates may presumably be influenced by the protein compliment of the multi-protein 
retrotranslocon complex and its correlated adaptors and effector proteins. 
Relatedly, we could not differentiate between ubiquitin chain linkage-
types/variations created by HRD1 on Tomo-1, in vivo or in vitro. Fascinatingly, specific 
mono- and poly-ubiquitin chain linkages, of which there are dozens predicted, are 
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increasingly implicated in the specific targeting of various substrates to their fates, 
notably including receptor internalization, nuclear localization, and proteasomal or 
lysosomal degradation (82-84). This knowledge will be important for the advancement 
of our understanding of Tomo-1-specific degradation by HRD1, but also the 
generalizable interpretation of these ubiquitin chain classes and their specific influences 
over synaptic and neuronal cell biology. Overexpression of the relatively well-
characterized ubiquitin mutants, including the K48R and K63R variants, would be 
particularly useful in examining this aspect of Tomo-1 regulation. 
Lastly, our present study was not designed to determine if the Tomo-1 or HRD1 
influences on spines was primarily implemented by modulating their morphogenesis, 
stability, retraction, or other temporally labile properties. Though all of the spine imaging 
reported in Chapter 2 was undertaken on single live neurons, we did so in individual 
sessions. It is extensively reported that dendritic spine dynamics and structural plasticity 
vary greatly following a number of conditions and treatments (85). Furthermore, we did 
not specifically examine potential effects on specific morphologically-defined dendritic 
spine sub-types (i.e. mushroom, filopodia) or effects of shaft branching. However, upon 
examination, we did not identify significant differences in the distribution of spines 
proximal or distal to the soma through the measured dendrite lengths. A repeat 
examination of Tomo-1 and HRD1 effects on the density and finer morphological 
characteristics of dendritic spines would greatly benefit from a timelapse imaging 
approach in examination of the onset, timecourse, and stability of spine density 
alterations. These results would be directly applicable to hypothesis generation for 
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downstream/emergent effects of intrinsic neuronal or network excitability and potential 
for induction of various physiologically-induced plasticities. At present, we can only 
speculate that the observed increase in dendritic spine density, defined as spine count 
over a given distance, directly correlates with concomitant effects on synapse number, 
distribution, sub-type proportion, and/or activity and plasticity. 
 
Chapter 3 
The ubiquitination of protein substrates at specific lysine residues is key to their 
targeted degradation. E3 ligases are the main mediator of protein targeting and often 
the individual residue targeting for ubiquitination. In the case of HRD1, as a RING-type 
E3, this process occurs in conjunction with its cognate upstream E2 conjugating 
enzyme (86). The target lysine residue is presumed to be poly-ubiquitinated alongside 
E4 conjugation factor proteins via either pre-constructed or salvaged chains (87) or 
iterative elongation initiating from the mono-ubiquitinated lysine. Our assays were 
unable to determine by which method poly-ubiquitination of Tomo-1 by HRD1 occurs 
upstream of its degradation. 
Gathering this information would be highly facilitated by more sensitive proteomic 
analysis, but moreover, by increased Tomo-1 protein expression and yield from intact 
neurons, as opposed to heterologous cell lines, for use in follow-up in vitro and in vivo 
assays. Toward this end, we have successfully inserted the WT and 12xKR constructs 
created and utilized in Chapter 3 into the lentiviral YFP-tagged vector utilized in Chapter 
2 for higher neuronal expression and greater yield during purification. These constructs 
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will be of immediate use in repeating the MS/MS experimental approaches following 
affinity-purification, rather than the lower yield Tomo-1 antibody-based IP purification, 
which indicated no reliable ubiquitination sites from neuronal samples. Furthermore, the 
inclusion of SILAC labeling for pulse-chase techniques and analysis should also prove 
worthwhile in the determination of relevant Tomo-1 ubiquitination events and sites in 
vivo. Tomo-1 antibody-based IPs also showed moderate levels of non-specific, 
presumably unrelated proteins in purified samples. The stronger and more specific 
biotin-streptavidin affinity in conjunction with the neuron-specific expression of the WT 
and 12xKR mutants should increase the probability of successful ubiquitination site 
identification from neuronal Tomo-1. This should then allow for comparison of WT and 
mutant (e.g. individual single site K-R mutants which were generated alongside the 
12xKR) constructs. Finally, these ubiquitination sites would serve as initial points of 
focus for the testing of relevant physiological conditions under which Tomo-1 
degradation may naturally be modulated. Those may include specific activity paradigms, 
homeostatic or Hebbian plasticity induction, and alongside co-manipulation of Taco-1 
effector molecules. These naturally-occurring variable conditions are hypothesized to 
also include cross-talk between PTMs (e.g. PO4, SUMO, targeted ubiquitination by 
other E3s). The research objectives of potential future experiments related to the 
findings outlined in this dissertation appear endless, and it will be quite interesting to 
see where hypothesis-driven examination leads the field of UPS-mediated synaptic 
regulation. 
 
	 152	
Final Remarks 
In summary, the collective work comprising this dissertation provides novel 
indications that Tomo-1, a potent negative regulator of presynaptic release, interacts 
with and is ubiquitinated and targeted for proteasomal degradation by the E3 ligase 
HRD1 (Chapter 2). Furthermore, these findings reveal that HRD1 modulates Tomo-1 
protein abundance in neurons, an interaction which appears to cooperatively regulate 
the density of postsynaptic dendritic spines. Relatedly, HRD1 is capable of 
ubiquitinating Tomo-1 at multiple specific lysine residues in vitro (Chapter 3), though 
which may be important for its targeted degradation and/or plasticity induction in vivo 
remains to be determined. These findings may prove useful in the future if integrated 
with related results regarding Tomo-1 and the UPS implications in the proteinopathy 
and protein aggregation associated effects apparent in neurological and 
neurodegenerative diseases such as Autism Spectrum Disorders, Alzheimer’s Disease, 
and Parkinson’s Disease. 
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Figure 4.1: Schematic model overviewing UPS-mediated Tomo-1 degradation. 
 
 
  
A.
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Figure 4.1: Schematic model overviewing UPS-mediated Tomo-1 degradation. 
 
A, Simplified cartoon model outlining the various UPS-related components and actions 
hypothesized to control Tomo-1 degradation in neurons. Ubiquitin molecules are 
activated by an E1 enzyme through an ATP-dependent process and transferred to a 
cognate E2 conjugating enzyme. This E2-ubiquitin then complexes with HRD1, which 
prompts the ubiquitin transfer to Tomo-1 as the target protein substrate. At present, it is 
unclear if this process occurs in an iterative fashion to accomplish ubiquitin chain 
elongation or if a pre-formed poly-ubiquitin chain may be transferred directly onto Tomo-
1 by the E2-HRD1 complex. Once poly-ubiquitinated, the Tomo-1 is then targeted and 
subject to degradation by the 26S proteasome complex, which subsequently cleaves 
the protein into polypeptide fragments and free ubiquitin molecules.  
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